



Annual report

2017

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making bladder cancer cells glow bright pink, has led to better health outcomes for bladder cancer patients. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO).

Photocure's strategy is to create a specialty pharmaceutical company maximizing its commercial presence and the opportunity of its flagship brand Hexvix®/Cysview® in bladder cancer. In addition, the Company will continue to explore alone or in partnership with others new product opportunities that is complementary to our commercial activities and expertise.

## Content

- 4 This year in brief
- 6 Board of Directors Report 2017
- 15 Confirmation from the Board of Directors and CEO 2017
- 16 Board of Directors
- 20 Corporate Governance Policy and Annual Review
- 28 Statement of Comprehensive Income
- 29 Statement of Financial Position
- 30 Statement of Changes in Equity
- 31 Statement of Cash Flows
- 32 Accounting principles 2017
- 40 Notes to the Financial Statements for 2017
- 60 Independent auditor's report
- 66 Alternative Performance Measures

ANNUAL  
GENERAL MEETING

May 9, 2018

Q1

May 23, 2018

Q2


August 8, 2018

Q3


November 8, 2018

# 2017

IN-MARKET UNIT SALES



SALES REVENUE - MNOK



P&amp;L PHOTOCURE TOTAL

| MNOK                        | FY 2017      | FY 2016      |
|-----------------------------|--------------|--------------|
| Hexvix / Cysview revenues   | 149.0        | 131.0        |
| Other sales revenues        | 0.2          | 5.2          |
| Signing fees and milestones | 1.7          | 7.4          |
| <b>Total revenues</b>       | <b>150.9</b> | <b>143.6</b> |
| Gross profit                | 138.9        | 134.3        |
| Operating expenses          | -168.0       | -142.3       |
| <b>EBITDA recurring</b>     | <b>-29.1</b> | <b>-8.0</b>  |
| One-Off items               | -4.0         | -            |
| EBITDA                      | -33.1        | -8.0         |
| Depreciation & Amortization | -12.1        | -7.9         |
| <b>EBIT</b>                 | <b>-45.2</b> | <b>-15.9</b> |
| Profit/loss(-) before tax   | -41.6        | 12.8         |
| <b>Net profit/loss (-)</b>  | <b>-34.7</b> | <b>35.3</b>  |

P&amp;L PHOTOCURE BY SEGMENT

| MNOK                           | FY 2017      | FY 2016      |
|--------------------------------|--------------|--------------|
| <b>COMMERCIAL FRANCHISE</b>    |              |              |
| Nordic revenues                | 43.3         | 39.0         |
| US revenues                    | 42.4         | 30.5         |
| Partner revenues               | 63.3         | 61.5         |
| <b>Hexvix/Cysview revenues</b> | <b>149.0</b> | <b>131.0</b> |
| Other revenues                 | 1.9          | 12.7         |
| Total revenues                 | 150.9        | 143.6        |
| Gross profit                   | 138.9        | 134.3        |
| Operating expenses             | -128.5       | 104.2        |
| <b>EBITDA recurring</b>        | <b>10.4</b>  | <b>30.0</b>  |
| <b>DEVELOPMENT PORTFOLIO</b>   |              |              |
| Operating expenses             | -39.5        | -38.1        |
| <b>EBITDA recurring</b>        | <b>-39.5</b> | <b>-38.1</b> |

# in brief

Sales revenue  
increase of

10%

Sales revenue for 2017 were  
NOK 149 million.

-33 MILL  
NOK

in consolidated EBITDA

129 MILL.  
NOK

in CASH balance at  
year end.

Revenue  
growth of

39%

in the  
U.S. operation

U.S. Cysview®

Reimbursement secured in  
U.S. hospital outpatient  
departments for certain Blue  
Light Cystoscopy (BLC™)  
with Cysview procedures.

Commercial segment  
EBITDA

10 MILL.  
NOK

Significant investments in  
the U.S. operation

U.S. Cysview®

U.S. FDA approval of an  
extension of the indication for  
BLC with Cysview to include  
flexible cystoscopies used for  
on-going surveillance of patients

## Board of Directors Report 2017

2017 has been a year with significant revenue growth for the Hexvix®/Cysview® brand. Furthermore, the position of Hexvix®/Cysview® in the treatment of bladder cancer is significantly strengthened with the inclusion and recommendation in the National Comprehensive Cancer Network (NCCN) guidelines in U.S. in 2016, the added reimbursement decided by U.S. Centers for Medicare & Medicaid Services (CMS) in 2017 and the recent approval from U.S. Food and Drug Administration (FDA) in 2018 of new indications for Blue Light Cystoscopy with Cysview®. Photocure believes these milestones combined with the investments in the U.S. bladder cancer business will enable further expansion in current as well as new market segments

The Company ended the year with sales revenues of NOK 149.2 million, an increase of 10% from 2016. Operating loss was NOK 45.2 million, an increase of NOK 29.3 million from 2016 operating loss of NOK 15.9 million. Net loss for the year was NOK 34.7 million compared to a profit in 2016 of NOK 35.3 million.

Full year in-market unit sales increased 2% in 2017. The growth was 31% in the U.S. and 3% in Nordic, while partner sales declined 1%.

The main development project in 2017 has been the phase 3 U.S. market expansion study for Blue Light Flexible Cystoscopy with Cysview®. The project was finalized as planned and the supplemental NDA was approved by U.S. Food and Drug Administration (FDA) February 2018.

### About Photocure

Photocure ASA (“Photocure”, “the Company” or “the Group”) delivers transformative solutions to improve the lives of bladder cancer patients. Photocure’s unique technology, making bladder cancer cells glow bright pink, has led to better health outcomes for bladder cancer patients. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO).

### Strategic direction – building a specialty pharmaceutical company

Photocure’s strategy is to create a specialty pharmaceutical company maximizing its commercial presence and the opportunity of its flagship brand Hexvix®/Cysview® in bladder cancer. In addition, the Company will continue to explore alone or in partnership with others new product opportunities that is complementary to the Company’s commercial activities and expertise.

### Commercial Segment

HEXVIX®/CYSVIEW® – THE INNOVATIVE PRODUCT FOR IMPROVED DETECTION AND MANAGEMENT OF BLADDER CANCER

Hexvix®/Cysview® is Photocure’s commercialized product and is the first significant advance for the improved detection and management of bladder cancer. The product is launched in all key European markets, in the U.S., Canada and Australia. In 2017 the in-market sales totaled NOK 256 million, compared to NOK 241 in 2016. Hexvix®/Cysview® is marketed in the U.S. and Nordics by Photocure’s own salesforce and through partnerships in continental Europe, Canada and Australia/New Zealand. The

Company continues to see significant growth opportunities in the U.S. and major European countries as well as the new territories Canada and Australia/New Zealand.

Photocure has made significant investments in the commercial and medical organization in U.S. to increase penetration of Cysview® in hospitals and urology practices. This investment has driven strong growth in revenues and number of Blue Light Cystoscopes (BLC™) installed at leading U.S. hospitals/urology centers. Revenue increased 39% in 2017 to NOK 42.4 million while the installed base increased with 25% to 104 at end of the year.

In November 2017, the United States Centers for Medicare & Medicaid Services (CMS) released the Final Rule stating that it will reimburse hospital outpatient departments for certain Blue Light Cystoscopy with Cysview® procedures beginning 1 January 2018. CMS has created a new set of codes specific to Blue Light Cystoscopy allowing for improved reimbursement for those procedures. The Company expects this to increase the installed base of BLC’s and drive revenue growth in 2018 and thereafter.

In February 2018, the U.S. Food and Drug Administration

(FDA) approved additional indications for BLC with Cysview® to include flexible cystoscopies, which are used in the long-term surveillance of patients with bladder cancer, often in outpatient settings. This new indication was granted based on the results from a large phase 3 study completed in 2017. The clinical safety and efficacy profile was confirmed in this study and the label now allows repeated use of Cysview®. In collaboration with KARL STORZ Endoscopy-America, Inc., Photocure plans to launch Cysview® in combination with blue light enabled flexible cystoscopy in mid-2018.

Supporting the sales activities has been the ongoing real-world registry study at nine sites across the U.S. At the end of 2017 1,000 patients were enrolled in the registry. This has and will continue to allow for publications and presentations of clinical data supporting the medical benefits of Hexvix®/Cysview®.

Sales in Nordic had a slow start in the beginning of 2017, however improved through the later part of the year. For the full year, sales revenue increased 11% to NOK 43.3 million. Market penetration in the Nordic countries was approximately 43%.



Partner sales has been a key challenge in 2017, growing 3% to NOK 63.3 million. Growth is driven by inventory buildup. However, in-market unit sales declined 1%.

Hexvix®/Cysview® has been launched in Canada and Australia, however volumes have been negatively impacted by the timing of the placement of scopes by third-party suppliers and health system funding approvals.

During 2017, several studies were published highlighting and confirming key clinical benefits including the positive impact of Hexvix®/Cysview® on reduced disease progression, bladder cancer detection and the safety of repeated use of Hexvix®/Cysview®.

Development Portfolio

VISONAC® – TREATMENT OF MODERATE TO SEVERE ACNE  
CEVIRA® – TREATMENT OF HPV AND PRECANCEROUS LESIONS OF THE CERVIX

Photocure has been developing two new late stage clinical products.

Visonac® has the potential to satisfy a high unmet medical need for a large acne patient population in need for alternatives to antibiotics and isotretinoin. Acne is the single most common skin disease worldwide, and affects up to 85% of all 12-24 year olds. Visonac® is being developed as the first photodynamic therapeutic option for this large patient population, which can easily be administered in dermatology offices.

Cevira® is a unique, non-invasive photodynamic therapy under development for the treatment of oncogenic human papilloma virus (HPV) infection. Cervical HPV and precancerous lesions of the cervix are highly prevalent diseases affecting an estimated 260 million women across the globe. The current treatment option is surgery, which carries increased risk of preterm miscarriage. Cevira® is being developed as the first novel non-surgical therapeutic option for this large and growing patient population.

Both Visonac® and Cevira® have shown medically relevant and statistically significant efficacy in multiple phase 2 studies in the target patients.

Based on this data, Photocure has obtained alignment with the FDA for both Visonac® and Cevira® on the phase 3 clinical devel-

opment program through the Special Protocol Assessment (SPA) process. Photocure will continue assessing further strategic alternatives for Visonac® and Cevira®.

Financial review

The Photocure annual accounts have been prepared in accordance with IFRS requirements as adopted by EU.

Total revenue reached NOK 150.9 million up from NOK 143.6 million in 2016. Revenue growth was mainly driven by positive developments in U.S., partly offset by reduced sales of Active Pharmaceutical Ingredients (API) and milestone revenues.

Sales revenues reached NOK 149.2 million in 2017, an increase of 10% from NOK 136.2 million in 2016. Sales revenues comprise own sales of Hexvix® in the Nordic region and Cysview® in the U.S., income from product sales and royalties from Photocure’s license partners on sales of Hexvix® to hospitals and pharmacies, and sale of API. Sale of API was NOK 0.2 million in 2017 and NOK 5.2 million in 2016. The API revenue in 2016 related to the agreement with Galderma after the divestment of Metvix®/Aktilite® which was discontinued from 2017.

Signing and milestone revenues totaled NOK 1.7 million in 2017 compared to NOK 7.4 million in 2016. Signing and milestones revenues include milestones from new partners, totaling NOK 1.7 million in 2017 and NOK 2.3 million in 2016. Furthermore, the revenues in 2016 include deferred revenue from the divestment of Metvix®/Aktilite® to Galderma. This deferred revenue was discontinued from 2017.

Operating expenses increased from NOK 150.2 million in 2016 to NOK 184.1 million in 2017. Main cost driver was the strategic investment in increased sales and marketing expenses in the U.S. sales operation. Photocure expenses all research and development costs with the exception of development costs related to the phase 3 clinical study for Cysview® which have been capitalized as intangible assets.

Photocure’s operating result was NOK -45.2 million in 2017, compared to an operating result of NOK -15.9 million in 2016. The change in the operating result is primarily attributable to the increase in sales and marketing costs in U.S. as well as reduced sales of API and reduced milestone revenues.

Net financial items totaled NOK 3.6 million in 2017, compared

to NOK 28.6 million in 2016. The net financial income in 2016 was driven by the sale of shares and subscription rights in PCI Biotech Holding.

Result before tax was a loss of NOK 41.6 million in 2017 compared to a profit of NOK 12.8 million in 2016.

Tax income was NOK 6.9 million in 2017 and NOK 22.5 million in 2016. The income in 2016 was driven by changes in transfer pricing principles which among other things resulted in a reallocation of historical losses carried forward.

The Group’s net result after tax is NOK -34.7 million in 2017 compared to NOK 35.3 million in 2016.

Net cash flow from operating activities was NOK -23.6 million in 2017, compared to NOK 19.2 million in 2016. In 2016 the net cash flow was driven by payment from Galderma related to the divestment of Metvix®, while 2017 net cash flow was driven by operational losses partly offset by improvements in working capital.

Photocure follows a low risk investment strategy for its liquid funds. The return on the liquid funds depends on the rate of interest in the money markets and will therefore vary over time. Liquid funds amounted to NOK 129.4 million at 31 December 2017 and NOK 169.2 million at 31 December 2016.

Shareholder equity was NOK 218.1 million at 31 December 2017, an equity ratio of 83%. At the end of 2016, shareholder equity was NOK 251.9 million (88%).

DIVIDEND

The Board does not propose a dividend payment for 2017. Photocure is focusing its resources on building a specialty pharma company and the Board of Directors will recommend payment of dividends in line with the Company’s results, financial position, product development plans and outlook. Photocure does not expect to pay dividends in the near future.

PARENT COMPANY

Photocure ASA (parent company) had in 2017 a loss after tax of NOK 27.7 million, compared to a profit after tax of NOK 41.2 million in 2016. The equity in Photocure ASA totals NOK 447.1 million at 31 December 2017. The equity ratio of the parent company is 92%.

SHARE CAPITAL AND BOARD MANDATES

At 31 December 2017, 21,557,910 shares were registered in Photocure. At the Ordinary General Meeting 27 April 2017, the Board of Directors was granted authorization to purchase up to 10% of its own shares. At 31 December 2017, Photocure held 809 own shares.

GOING CONCERN

Pursuant to § 3.3 (a) of the Norwegian Accounting Act, it is confirmed that the conditions for assuming that the Group is a going concern are present, and that the financial statements have been prepared on the basis of this assumption. No events have occurred since the end of 2017, except those which are stated in this report that are of major significance for the assessment of the Company’s financial position and results.

Operational risk

Photocure develops innovative products and markets and sells these products through its own commercial teams and in partnerships with other companies. These activities entail exposure to various risks. The Board of Directors and management monitor and analyze the operations and potential risk factors, and actively take risk reduction measures.

COMMERCIAL RISK

Photocure is commercializing Hexvix®/Cysview® directly in the U.S. and the Nordic region, and has a strategic partnership with Ipsen for the commercialization of Hexvix® in Europe, excluding the Nordic region, and with Juno Pharmaceuticals and BioSyent Pharma for Australia/New Zealand and Canada respectively. Any significant event that adversely affects revenues from Hexvix®/Cysview® could have a material and negative impact on Photocure’s results and cash flows. Key commercial risks include:

- Partners ability to support the brand in key markets.
- Reimbursement may be limited or unavailable in certain markets, which could make it more difficult to achieve profitability in these markets.
- The expiration or loss of patent protection may adversely affect Photocure’s future results and cash flows. Third parties may challenge or seek to invalidate or circumvent Photocure’s patents and patent applications.
- Although management is currently unaware of any such developments, competitive products or technologies may emerge at any time.



MANUFACTURING RISK

Delays or interruptions at the production facilities may impair Photocure’s supply of clinical trial material for pipeline products and supply of Hexvix®/Cysview® to the market and hence revenues.

DEVELOPMENT AND REGULATORY RISK

Photocure has currently two products under development, Visionac® and Cevira®. Key development risks include:

- Development of Photocure’s products is associated with inherent risk. Inter alia, development is subject to obtaining adequate funding as well as technological risks.
- The further development of Photocure’s near-term pipeline may be dependent on partnering agreements with third parties.
- Photocure or its future partners will need approval from regulatory authorities to market its pipeline products. Efficacy issues could arise and approval may be denied, delayed or limited.
- Successful launches and sales for pipeline products may not be achieved inter alia due to changes in market dynamics or

- competition, unsuccessful marketing, and pricing pressure due to limitations on healthcare budgets.
- As with any drug intended for diagnostic or therapeutic use, adverse clinical reactions are always a possibility.

Financial risk

Photocure has an international business operation and is exposed to currency risk, interest rate risk, commodity price risk, liquidity risk and credit risk. At the end of 2017, the Company has no derivatives or other financial instruments to reduce these risks.

Responsibility for managing financial risk is placed with the management of the Company. Financial risk is also monitored by the Board of Directors.

INTEREST RATE RISK

Photocure does not have any interest-bearing debt, and the Company’s interest rate risk is mainly associated with the Company’s holdings of cash and cash equivalents. The main strategy is to diversify the risk and invest in money market funds and

bond funds with low risk, high liquidity and short duration. The investments are denominated in NOK.

LIQUIDITY RISK

The Company monitors the cash flows from both long and short-term perspectives through planning and reporting. Photocure does not have any loan agreements that involve covenants or other financial requirements. Photocure uses a multi-currency consolidated accounts system that provides flexibility in relation to drawing on multiple currencies.

CREDIT RISK

Photocure is primarily exposed to credit risk associated with accounts receivable and other short-term receivables. Photocure’s sales are mainly to license partners, pharmaceutical wholesalers in the Nordic region and hospitals in the U.S. The credit risk is limited as the counterparties are mainly large companies/hospitals that are not related to each other. Photocure’s credit risk is considered moderate and the Company does not use credit insurance.

CURRENCY RISK

As NOK is the Company’s presentation currency, Photocure is exposed to translation risk associated with the Company’s net exposure in foreign currency. Photocure’s revenues and costs are accrued in different currencies and the Company is therefore exposed to exchange rate fluctuations. The Company monitors the need for hedging of large transactions on an ongoing basis. Photocure did not have outstanding hedging of future transactions at 31 December 2017.

Organization

The Group’s senior management team at year-end consists of Kjetil Hestdal, President and CEO; Erik Dahl, Chief Financial Officer; Jeremy Bahr, Chief Business Officer; Grete Hogstad, Vice President Strategic Marketing; Inger Ferner Heglund, Vice President Research and Development; Gry Stensrud, Vice President Technical Development and Operations; Ambaw Bellete, Head, U.S. Cancer Commercial Operations and Espen Njåstein, Head, Nordic Cancer Commercial Operations.

The Board of Directors held 17 meetings in 2017. All members of the Board of Directors are shareholder-elected. The members of the Board of Directors were at the end of 2017 Jan H. Egberts (Chairperson), Johanna Holldack, Gwen Melincoff, Tom Pike, Synne H. Røine, Grannum Sant and Xavier Yon.

Photocure ASA has offices in Oslo, Norway. Photocure ASA has one subsidiary, Photocure Inc, located in Princeton, New Jersey, USA.

Corporate social responsibility

Photocure’s corporate social responsibility guidelines are available on [www.photocure.com](http://www.photocure.com).

Photocure is a specialty pharma company that delivers transformative solutions for detecting and treating bladder cancer to

improve the lives of patients. The Company consistently aims to create innovative drugs, procedures and medical devices that help urology providers deliver improved bladder cancer outcomes to their patients. Through Photocure’s end-to-end insight and bladder cancer expertise, the Company provides smarter solutions to existing challenges and are shaping the future of bladder cancer treatment.

Photocure believes that creating value for patients, customers and society strengthens the Company’s business and provides value for shareholders, and that the commitment to corporate social responsibility will enhance this by building strong relationships with stakeholders.

Photocure’s commitment to corporate social responsibility is driven by the Company values – care, courage and passion – and is reflected in the focus on the following priority areas: Patients

access to health and quality of life, human resources, environment, governance and ethics.

PATIENTS ACCESS TO HEALTH AND QUALITY OF LIFE

Photocure’s mission is to deliver transformative solutions to improve the lives of bladder cancer patients.

This mission encompasses all activities from developing products, gaining approval by relevant authorities, working with patient organizations and hospitals and finally getting the products to the market either through Photocure’s own sales organization or by partners.

Through efforts made by Photocure and its partners, more bladder cancer patients gained access to Hexvix®/Cysview® and its possible positive impact on management of these patients.

The Company is continuously supporting clinical studies. Documented clinical benefits for bladder cancer patients using Hexvix®/Cysview® have been published in World Journal of Urology, Scandinavian Journal of Urology and The Journal of Urology during this year. Photocure aims to provide patients in new territories access to Hexvix®/Cysview®. Significant progress have been achieved by the Company’s distributors in Canada, Australia and New Zealand.

HUMAN RESOURCES

The Photocure organization comprised of 60 employees in Nordics and the U.S. at the end of 2017. In addition, the Company has a strong network of consultants to further the development of the pipeline products. The Company’s policy is to outsource non-core operations and highly specialized services. The work environment within the Company is considered to be good. No accidents or injuries resulting in absence were registered in 2017. Absence due to illness in the Company was 2.4% of total hours in 2017.

Photocure aims to be a workplace with equal opportunities in all areas. The Company has traditionally recruited from environments where the number of women and men is relatively equally represented. In terms of gender equality within the Company, 43% of board members are women, as are 38% of the senior management team. Working time arrangements at the Company are independent of gender.

Photocure’s policy is to promote equal rights and opportunities and prevent discrimination based on gender, ethnicity, nationality, sexual orientation, ancestry or religion. Photocure is working actively to promote the anti-discrimination act. These activities include recruitment, salary and working conditions, promotion, professional development and protection against harassment.

Photocure aims to be a workplace where there is no discrimination on the basis of disability. Photocure works actively to design and facilitate the physical environment so that the Company’s various functions can be used by as many as possible.

ENVIRONMENT

The Company does not pollute the external environment to a greater extent than is normal for this type of industry. All production and distribution is outsourced. In selection of suppliers,



ethical and responsible business conduct including environment, health and safety policy of the supplier is evaluated.

GOVERNANCE AND ETHICS

Ensuring good governance practices involves all people in Photocure. This includes governance as documented in the guidelines for corporate governance, ethical conduct and anticorruption based on the Photocure values and respect for human rights. Photocure’s supplier requirements in terms of adherence to Company practices, guidelines and values are an integral part of all stages of the procurement process including selection and auditing.

Photocure’s values set out the expectation that everyone behaves ethically in everything they do. The Company values are care, courage and passion. The annual performance appraisal for Photocure employees and management includes an assessment of the performance in relation to the values.

Photocure considers solid corporate governance as a prerequisite to creating value for shareholders and gaining the confidence of investors. Photocure will strive to comply with the generally accepted principles of good corporate governance through its internal controls and management structure. Photocure believes that its current guidelines for corporate governance are in line with the latest version of the Norwegian Code of Practice for Corporate Governance, and a description of this is given at the end of the Annual report. A complete description of the recommendation is available at the Norwegian Corporate Governance Board (NCGB) web pages ([www.nues.no](http://www.nues.no)).

Subsequent events

Photocure is not aware of any events after year-end that would

be of significance to the financial statements for the year ended 31 December 2017.

Outlook

Photocure has built considerable experience in the bladder cancer market through its Hexvix®/Cysview® franchise and sees significant long-term value creation potential in this market segment. The Company aims to capitalize on the inclusion of Cysview® in the NCCN guidelines, as well as the increased patient awareness and the improved reimbursement of Cysview® in the outpatient TURBT procedures with rigid scopes, to significantly increase penetration in the U.S. market. Furthermore, a significant market opportunity has opened up in the surveillance segment with the approval of Cysview® to include flexible cystoscopies.

Photocure believes that in order to increase market share in the U.S., an investment in the U.S. commercial and medical infrastructure is required. The Company has invested significantly in increased sales force in 2017 and will continue to invest in 2018. These investments will enable the Company to drive the U.S. revenues in 2020 to a range of USD 20-25 million, however with upside potential driven by added reimbursement and penetration of the surveillance segment. The Company will update the market on this outlook later in 2018 when there is better visibility on the effects of the new reimbursement and initial market response in the surveillance segment.

As a result of the increased activity level in U.S., the added operating expenses has contributed to an EBITDA decline for the group in 2017. This will continue in 2018. The Company is however fully funded for this market strategy.

Confirmation from the Board of Directors and CEO 2017

We confirm that, to the best of our knowledge, that the financial statements for the period from 1 January to 31 December 2017 have been prepared in accordance with IFRS adopted by EU and gives a true and fair view of the Group and the Company’s consolidated assets, liabilities, financial position and results of operations, and that the Report of the Board of Directors provides a true and fair view of the development and performance of the business and the position of the Group and the Company together with a description of the key risks and uncertainty factors that the Company is facing.

Oslo, 16 April 2018  
The Board of Directors of Photocure ASA

Jan H. Egberts  
Chairperson

Johanna Holldack  
Director

Gwen Melincoff  
Director

Tom Pike  
Director

Synne H. Røine  
Director

Grannum R. Sant  
Director

Xavier Yon  
Director

Kjetil Hestdal  
President and CEO

Oslo, 16 April 2018  
The Board of Directors of Photocure ASA

Jan H. Egberts  
Chairperson

Johanna Holldack  
Director

Gwen Melincoff  
Director

Tom Pike  
Director

Synne H. Røine  
Director

Grannum R. Sant  
Director

Xavier Yon  
Director

Kjetil Hestdal  
President and CEO

# Board of Directors



Jan H. Egberts

Chairperson of the Board/Member of Compensation Committee  
Attendance: Board meetings: 12/12  
Compensation Committee: 3/3

Jan H. Egberts holds no shares and no share options in Photocure.

Dr. Egberts has over 25 years of experience in the pharmaceutical and medical devices sector. Currently, Dr. Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on investments in the healthcare industry. Previous positions include strategic consultant at McKinsey & Co. in New York, various business development and general management positions in the USA at Merck & Co. and Johnson & Johnson, Senior Advisor, Healthcare Investments for 3i, CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands, and Board member and interim CEO of Agendia, a molecular diagnostics company.

- Elected year 2017
- Position: Managing Partner of Veritas Investments
- Education: MD and MBA
- Other assignments: Board member at Pharming, Implanet, LeadPharma, CHDR, SigmaScreening and Mellon Medical



Johanna Holldack

Director  
Attendance: Board meetings: 12/12

Johanna Holldack holds no shares and no share options in Photocure.

Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years. Her industry career spans over 20 years including management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation.

- Elected year 2017
- Position: Independent consultant
- Education: MD
- Other assignments: Chairperson at Amal Therapeutics



Gwen Melincoff

Director/Member of the Audit Committee  
Attendance: Board meetings: 12/12  
Audit Committee: 2/2

Gwen Melincoff holds no shares and no share options in Photocure.

Gwen Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. From 2014 to 2016, she served as Vice President of Business Development at BTG International Inc., and from 2004 to 2013, she was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, she led the Strategic Investment Group (SIG), Shire's \$50MM corporate venture fund which was started in 2010.

- Elected year 2017
- Position: Independent consultant
- Education: B.S in Biology, M.Sc. in Management
- Other assignments: Board member at Kamada and Collegium Pharmaceutical Inc.



Tom Pike

Director/Chairperson of the Compensation Committee  
Attendance: Board meetings: 16/17  
Audit Committee: 3/3  
Compensation Committee: 3/3

Tom Pike holds 3,400 shares and no share options in Photocure.

Tom Pike serves as Chairperson of Vaccibody, and has been associated with the pharmaceutical industry in Norway for many years. Previous positions include Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway. He has worked at Hoffman La-Roche in Norway and Switzerland for 18 years, including 8 years as general manager in Norway.

- Elected year 2014
- Position: Life Science Industry Professional
- Education: B.Sc. Honors in Pharmacology
- Other assignments: Chairperson at Vaccibody AS, Clanotech AB, ACD Pharmaceuticals AS and Credio AS. Board member at Vectron Biosolutions AS and Vingmed Holding AS



Synne H. Røine

Director/Chairperson of the Audit Committee  
Attendance: Board meetings: 17/17  
Audit Committee: 5/5

Synne H. Røine holds no shares and no share options in Photocure.

Synne H. Røine is Partner at Serendipity Partners, a private investment company focused on healthcare. Ms. Røine served as CFO of Colosseum Dental Group from 2015 to 2017, a leading provider of dental care in Europe, and as CFO of Bionor Pharma ASA from 2013 to 2015, a biotechnology company developing therapeutic vaccines against viral diseases. From 2009 to 2013 she was CFO of Pronova BioPharma ASA, which develops and sells Omega-3 based pharmaceuticals.

- Elected year 2014
- Position: Partner at Serendipity Partners
- Education: M.Sc.



Grannum R. Sant

Director/Member of the Audit Committee  
Attendance: Board meetings: 17/17  
Audit Committee: 3/3

Grannum R. Sant holds no shares and no share options in Photocure.

Dr. Sant has a broad and deep international experience in pharma and academia. From 2003 to 2013 he held senior leadership roles including Vice President and Head of Medical Affairs for urology and oncology at Sanofi US. His last pharma position (2010-2013) was as Vice President, Head of Global Medical Affairs Rare Genetic Diseases at Genzyme. Dr. Sant is a board-certified urologist in the US and prior to 2003 was Professor and Chair of the Urology at Tufts University School of Medicine.

- Elected year 2016
- Position: Independent consultant and Professor of Urology at Tufts University School of Medicine in Boston, USA
- Education: MD (Dublin University), FRCS, FACS
- Other assignments: Board Member Cellanyx and Xennials Therapeutics, Scientific Advisory Board Cellanyx and EmpiraMed



Xavier Yon

Director/Member of the Compensation Committee  
Attendance: Board meetings: 17/17  
Compensation Committee: 7/7

Xavier Yon holds no shares and no share options in Photocure.

As a former President and CEO of Galderma, Xavier Yon has spent more than 40 years in the pharmaceutical industry. He has previously worked for Pfizer, Solvay Pharma and Alcon before starting as President and CEO of Galderma in 1989. Under Xavier Yon's leadership Galderma grew into being a leading dermatology company globally.

- Elected year 2011
- Position: Managing Director, XY Consulting
- Education: Degree in physics, chemistry and biology from Sorbonne University, Paris
- Other assignments: Director Virbac Animal Health (France) since 2004, Director Elastagen (Australia) since 2011, Director Michelson Diagnostics (UK) since 2012

# Corporate Governance Policy and Annual Review

Review of policy adopted by the Board 16 April, 2017

## Photocure is committed to Good Corporate Governance

Photocure ASA the (“Photocure” or the “Company”) has made a strong commitment to ensure trust in the Company and to enhance shareholder value through effective decision-making and improved communication between the management, the board of directors and the shareholders. The Company’s framework for corporate governance is intended to decrease business risk, maximize value and utilize the Company’s resources in an efficient, sustainable manner, to the benefit of shareholders, employees and society at large.

The Company will seek to comply with the Norwegian Code of Practice for Corporate Governance (the “Corporate Governance Code”), last revised on 30 October 2014 and available at the Norwegian Corporate Governance Committee’s web site [www.nues.no](http://www.nues.no), to the extent not considered unreasonable due to the Company size and stage of development. The principal purpose of the Corporate Governance Code is to ensure (i) that listed companies implement corporate governance that clarifies the respective roles of shareholders, the board of directors and senior management more comprehensively than what is required by legislation and (ii) effective management and control over activities with the aim of securing the greatest possible value creation over time in the best interest of companies, shareholders, employees and other parties concerned.

The Company is subject to reporting requirements for corporate governance under the Accounting Act section 3-3b as well as Oslo Børs “Continuing obligations of stock exchange listed companies” section 7. The board of directors will include a report on the Company’s corporate governance in each annual report including an explanation of any deviations from the Corporate Governance Code. The corporate governance framework of the Company is subject to annual reviews and discussions by the board of directors.

The following provides a discussion of the Company’s corporate governance in relation to each section of the Corporate Governance Code for the financial year 2017. Photocure’s compliance with the Code is detailed in this report and section numbers refer to the Corporate Governance Code:

## 1. Implementation and reporting on Corporate Governance

The board of directors of the Company has adopted several

corporate governance guidelines, including rules of procedure for the board of directors, instructions for the audit committee, instructions for the compensation committee, insider manuals, manual on disclosure of information, ethical guidelines and guidelines for corporate social responsibility.

The Company will seek to comply with the Corporate Governance Code. The board of directors shall include a report on the Company’s corporate governance in its annual report, including an explanation of any deviations from the Corporate Governance Code.

Photocure’s value base constitutes a key premise for the Company’s corporate governance. The key values of the Company are care, courage and passion. These values aim to characterize the behavior of the Company and the Company’s employees, and form the basis for the Company’s ethical guidelines.

**Non-conformance with the recommendation: None**

## 2. Business

Photocure’s business is clearly defined in the Company’s articles of association (the “Articles of Association”). The Company’s goals and strategies are presented in the annual report, and the Company’s website [www.photocure.com](http://www.photocure.com).

The Company’s business is defined in the following manner in the Articles of Association section 3:

“The purpose and main business of the Company is to operate business related to medical use of photodynamic technology and other medical methods of treatment, and anything thereby connected.”

**Non-conformance with the recommendation: None**

## 3. Equity and dividends

### EQUITY

At 31 December 2017, the Company’s consolidated equity was NOK 218.1 million, an equity ratio of 83%. The board of directors considers this equity level to be satisfactory. The Company’s equity level and financial strength is continuously considered in light of its objectives, strategy and risk profile.

### DIVIDEND POLICY

Photocure is focusing its resources on building a specialty pharma company and the board of directors will recommend payment of dividends in line with the Company’s results, financial position, product development plans and outlook. Photocure does not expect to pay dividends in the near future.

The ordinary general meeting resolves the annual dividend, based on the proposal by the board of directors. The amount proposed sets an upper limit for the general meeting’s resolution.

### CAPITAL INCREASES AND ISSUANCE OF SHARES

The board of directors’ is authorized by the general meeting to resolve increases of the Company’s share capital. The authorization is restricted to defined purposes, and does not last longer than to the Company’s next annual general meeting.

### PURCHASE OF OWN SHARES

The board of directors’ is authorized by the general meeting to purchase the Company’s own shares on behalf of the Company. The authorization is restricted to defined purposes, and does not last longer than to the Company’s next annual general meeting.

**Non-conformance with the recommendation: None**

## 4. Equal treatment of shareholders and transactions with related parties

### CLASS OF SHARES

The Company has one class of shares. All shares carry equal rights in the Company, and the Articles of Association do not contain any provisions restricting the exercise of voting rights.

### PRE-EMPTION RIGHTS TO SUBSCRIBE

According to the Norwegian Public Limited Liability Companies Act, the Company’s shareholders have pre-emption rights in share offerings against cash contribution. Such pre-emption rights may however be set aside, either by the general meeting or by the board of directors if the general meeting has granted a board authorization which allows for this. Any resolution to set aside pre-emption rights will be justified by the common interests of the Company and the shareholders, and such justification will be publicly disclosed through a stock exchange notice from the Company.

### TRADING IN OWN SHARES

Photocure owns a total of 809 own shares. Photocure has not acquired any own shares during 2017.

In the event of a future share buy-back program, the board of directors will aim to ensure that all transactions pursuant to such program will be carried out either through the trading system at Oslo Børs or at prevailing prices at Oslo Børs. In the event of such program, the board of directors will take the Company’s and shareholders’ interests into consideration and aim to maintain transparency and equal treatment of all shareholders. If there is limited liquidity in the Company’s shares, the Company shall consider other ways to ensure equal treatment of all shareholders.

### TRANSACTIONS WITH CLOSE ASSOCIATES

The board of directors aims to ensure that any not immaterial future transactions between the Company and shareholders, a shareholder’s parent Company, members of the board of directors, executive personnel or close associates of any such parties are entered into on arms-length terms. For any such transactions which do not require approval by the general meeting pursuant to the Norwegian Public Limited Liability Companies Act, the board of directors will on a case-by-case basis assess whether a fairness opinion from an independent third party should be obtained.

### GUIDELINES FOR DIRECTORS AND SENIOR MANAGEMENT

The board of directors has adopted rules of procedures for the board of directors which inter alia includes guidelines for notification by members of the board of directors and senior management if they have any material direct or indirect interest in any transaction entered into by the Company.

**Non-conformance with the recommendation: None**

## 5. Freely negotiable shares

The shares of the Company are freely transferable. There are no restrictions on transferability of shares pursuant to the Articles of Association.

**Non-conformance with the recommendation: None**

6. General meetings

The board of directors will make its best efforts with respect to the timing and facilitation of general meetings to ensure that as many shareholders as possible may exercise their rights by participating in general meetings, thereby making the general meeting an effective forum for the views of shareholders and the board of directors.

NOTIFICATION

The notice for a general meeting, with reference to or attached support information on the resolutions to be considered at the general meeting, shall as a principal rule be sent to shareholders individually, or to their depository banks, no later than 21 days prior to the date of the general meeting. The notice of meeting includes information regarding shareholders’ rights, guidelines for registering and voting at the meeting.

The board of directors will seek to ensure that the resolutions and supporting information distributed are sufficiently detailed and comprehensive to allow shareholders to form a view on all matters to be considered at the meeting. The notice and support information, as well as a proxy voting form, will normally be made available on the Company’s website www.photocure.com no later than 21 days prior to the date of the general meeting.

PARTICIPATION AND EXECUTION

Pursuant to the Articles of Association section 9 shareholders who want to participate at the general meeting shall notify the Company thereof within five days prior to the general meeting

To the extent deemed appropriate or necessary, the board of directors will seek to arrange for the general meeting to vote separately on each candidate nominated for election to the Company’s corporate bodies.

The chairperson of the board, the chief executive officer and the chief financial officer are present at the annual general meeting. The board of directors and the nomination committee shall, as a general rule, be present at general meetings. The auditor will attend the ordinary general meeting and any extraordinary general meetings to the extent required by the agenda items or other relevant circumstances.

The chairperson of the board will normally be chairing the general meetings. The board of directors will seek to ensure that an independent chairperson is appointed if considered necessary based on the agenda items or other relevant circumstances.

The Company will aim to prepare and facilitate the use of proxy forms which allows separate voting instructions to be given for each item on the agenda, and nominate a person who will be available to vote on behalf of shareholders as their proxy.

Non-conformance with the recommendation: Photocure is a small company and with directors living abroad, the company has so far not required directors’ attendance in general meeting.

7. Nomination Committee

The nomination committee is governed by the Articles of Association section 7. In addition, the Company’s general meeting adopts instructions for the nomination committee.

The nomination committee shall consist of two or three members who shall be shareholders or shareholder representatives. The members shall be elected by the general meeting for a term of one year. The nomination committee shall give its recommendation to the general meeting on election of and compensation to members of the board of directors, in addition to election of members of the nomination committee. The proposals shall be justified.

The nomination committee currently consists of the following three members: Hans Peter Bøhn (chairperson), Dan Mahoney, and James McDonald. The current members have been elected by the general meeting with a term until the Company’s ordinary general meeting in 2018. All members are independent of the board of directors and senior management.

Non-conformance with the recommendation: None

8. Composition and independence of the Board of Directors

Pursuant to the Articles of Association section 5, the Company’s board of directors shall consist of three to seven members. The board of directors currently consists of the following seven members: Jan H Egberts (chairperson), Johanna Holldack, Gwen Melincoff, Tom Pike, Synne H. Røine, Grannum R. Sant and Xavier Denis Yon. The chairperson of the board has been elected by the general meeting. The term of office for members of the board of directors is one year at a time.

All members of the board are considered independent of the Company’s senior management, material business contacts and

the Company’s main shareholders.

The Company’s annual report provides information to illustrate the expertise of the members of the board of directors and their record of attendance at board meetings.

Non-conformance with the recommendation: None

9. The work of the Board of Directors

THE RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS

The board of directors is responsible for the over-all management of the Company, and shall supervise the Company’s day-to-day management and the Company’s activities in general.

The Norwegian Public Limited Liability Companies Act regulates the duties and procedures of the board of directors. In addition, the board of directors has adopted supplementary rules of procedures, which provides further regulation on inter alia the duties of the board of directors and the chief executive officer, the division of work between the board of directors and the chief executive officer, the annual plan for the board of directors, notices of board proceedings, administrative procedures, minutes, board committees, transactions between the Company and the shareholders and confidentiality.

The board shall produce an annual plan for its work, with particular emphasis on objectives, strategy and implementation. The chief executive officer shall at least once a month, by attendance or in writing, inform the board of directors about the Company’s activities, position and profit trend.

The board of directors’ consideration of material matters in which the chairperson of the board is, or has been, personally involved, shall be chaired by some other member of the board.

The board of directors shall evaluate its performance and expertise annually, and make the evaluation available to the nomination committee.

THE AUDIT COMMITTEE

The Company’s audit committee is governed by the Norwegian Public Limited Liability Companies Act and a separate instruction adopted by the board of directors.

The members of the audit committee are appointed by and among the members of the board of directors. A majority of the members shall be independent of the Company’s senior management, and at least one member shall have qualifications within accounting or auditing. Board members who are also members of the senior management cannot be members of the audit committee.

The principal tasks of the audit committee are to:

- prepare the board of directors’ supervision of the Company’s financial reporting process;
- monitor the systems for internal control and risk management;
- have continuous contact with the Company’s auditor regarding the audit of the annual accounts; and
- review and monitor the independence of the Company’s auditor, including in particular the extent to which services other than auditing provided by the auditor or the audit firm represent a threat to the independence of the auditor.

The audit committee currently consists of the following three members: Synne H. Røine (chairperson), Gwen Melincoff and Grannum R. Sant.

THE COMPENSATION COMMITTEE

The Company’s compensation committee is governed by a separate instruction adopted by the board of directors. The members of the compensation committee are appointed by and among the members of the board of directors, and shall be independent of the Company’s senior management.

The principal tasks of the compensation committee are to prepare:

- the board of directors’ declaration on determination of salaries and other remuneration for senior management in accordance with the Norwegian Public Limited Liability Companies Act section 6-16a; and
- other matters relating to remuneration and other material employment issues in respect of the senior management.

The compensation committee currently consists of the following three members: Tom Pike (chairperson), Jan H. Egberts and Xavier Denis Yon.

Non-conformance with the recommendation: None



10. Risk management and internal control

The board of directors should on an ongoing basis assess the Company’s risks. Each year, as a minimum, the board of directors has a thorough assessment of the significant parts of the Group’s business and outlook, in order to identify risks and potential risks, and remedy any incident that have occurred. The board of directors may engage external expertise if necessary. The objective is to have the best possible basis for, and control of, the Company’s situation at any given time.

In addition to the annual risk assessment, the management should present quarterly financial statements that will inform the board and shareholders on current business performance, including risk. These reports should be subject to review at the board meetings.

Significant risks include strategic risks, financial risks, liquidity risks and operational risks including risks related to development of products. The Company’s significant risks are assessed on an ongoing basis and at least once a year by the board.

The Company’s finance function is responsible for the preparation of the financial statements and to ensure that these are prepared and reported according to applicable laws and regulations

and in accordance with IFRS. The audit committee performs reviews of the quarterly and annual financial statements with special focus on transaction types which includes judgments, estimates or issues with major impact on the financial statement. In addition to the quarterly and annual reporting, the board of directors receives monthly financial updates. Management controls are performed at a senior level in the Company.

Non-conformance with the recommendation: None

11. Remuneration of the Board of Directors

The remuneration of the board of directors shall be decided at the Company’s general meeting, and should reflect the board of directors’ responsibility, expertise, time commitment and the complexity of the Company’s activities. The remuneration is not linked to the Company’s performance. The nomination committee shall give a recommendation as to the size of the remuneration to the board of directors. Pursuant to the instructions for the nomination committee, the recommendation should normally be published on the Company’s website at least 21 days prior to the general meeting that will decide on the remuneration.

The nomination committee has recommended a program whereby the members of the Board may choose to receive all or part of their remuneration in the form of restricted stock units (RSUs). The RSUs will be non-transferrable and each will give the right and obligation to acquire shares in the Company after the first anniversary of the general meeting resolving the remuneration to the Board, subject to certain terms and conditions. The RSU program is proposed to strengthen the company’s ability to attract eligible board members with appropriate competence and international experience, and to facilitate ownership in the Company by the Board.

The Company has not granted share options to board members.

Any remuneration in addition to normal fees to the members of the Board should be specifically identified in the annual report.

Members of the board of directors and/or companies with which they are associated should not take on specific assignments for the Company in addition to their appointment as a member of the board unless approved by the board of directors. The remuneration for such additional duties should be approved by the board of directors.

Non-conformance with the recommendation: None

12. Remuneration of the senior management

The board of directors shall in accordance with the Norwegian Public Limited Liability Companies Act prepare separate guidelines for the stipulation of salary and other remuneration to key management personnel. The guidelines shall include the main principles applied in determining the salary and other remuneration of the senior management, and shall ensure convergence of the financial interests of the senior management and the shareholders. It should be clear which aspects of the guidelines that are advisory and which, if any, that are binding thereby enabling the general meeting to vote separately on each of these aspects of the guidelines.

The board of directors aims to ensure that performance-related remuneration of the senior management in the form of equity-based compensation, annual bonus programs or the like, if used, are linked to value creation for shareholders or the Company’s earnings performance over time. Performance-related remuneration should be subject to an absolute limit. Furthermore, the Company aims to ensure that such arrangements are based on

quantifiable factors which the employee in question can influence.

The board of directors has established guidelines for remuneration of the key employees of the Company, and the guidelines will be presented to the annual general meeting in 2018. The remuneration guidelines are included in note 22 to the annual accounts. The compensation scheme for the Company’s senior management is based on a fixed salary, performance related bonus (capped based on fixed salary) and a restricted shares program. Performance-related remuneration is linked to value creation for the shareholders over time, and is based on quantifiable factors which the employees in question can influence.

Non-conformance with the recommendation: None

13. Information and communications

GENERAL

The Company has targeted investor relation activities with the aim to consistently provide the market with timely and accurate information.

The Company’s reporting of financial and other information is based on openness and takes into account requirements for equal treatment of all investors.

The board of directors has adopted a separate manual on disclosure of information, which sets forth the Company’s disclosure obligations and procedures. The board of directors will seek to ensure that market participants receive correct, clear, relevant and up-to-date information in a timely manner, taking into account the requirement for equal treatment of all participants in the securities market.

The Company will each year publish a financial calendar, providing an overview of the dates for major events such as its ordinary general meeting and publication of interim reports.

INFORMATION TO SHAREHOLDERS

The Company shall have procedures for establishing discussions with important shareholders to enable the Board to develop a balanced understanding of the circumstances and focus of such shareholders. Such discussions shall be done in compliance with the provisions of applicable laws and regulations. All information distributed to the Company’s shareholders will be published on the Company’s web site at the same time as it is

sent to shareholders. The chairperson of the board and the chief executive officer are authorized to speak on behalf of the Company, and delegate such authority as is appropriate in relevant cases.

Non-conformance with the recommendation: None

14. Take-overs

In the event the Company becomes the subject of a take-over offer, the board of directors shall ensure that the Company’s shareholders are treated equally and that the Company’s activities are not unnecessarily interrupted. The board of directors shall also ensure that the shareholders have sufficient information and time to assess the offer.

The board of directors will not attempt to influence, hinder or complicate the submission of bids for the acquisition of the Company’s operations or shares, or prevent the execution thereof. There are no defense mechanisms against take-over bids in the Articles of Association, nor have other measures been implemented to specifically hinder acquisitions of shares in the Company. The board of directors has not established written guiding principles for how it will act in the event of a take-over bid, as such situations are normally characterized by concrete and one-off situations which make a guideline challenging to prepare.

In the event a take-over was to occur, the board of directors will consider the relevant recommendations in the Corporate Governance Code and whether the concrete situation entails that the recommendations in the Corporate Governance Code can be complied with or not.

Non-conformance with the recommendation: The Company has not established separate principles for how to act in a take-over situation as described

15. Auditor

The Company’s external auditor is KPMG AS.

On an annual basis, the auditor presents to the audit committee a review of the Company’s internal control procedures, including identified risk areas and proposals for improvement, as well as the main features of the plan for the audit of the Company.

Furthermore, the auditor participates in meetings of the board of directors that deal with the annual accounts and, at least once a year, carries out a review of the Company’s procedures for internal control in collaboration with the audit committee. At least one board meeting with the auditor shall be held each year in which no member of the senior management is present.

The board of directors has established guidelines in respect of the use of the auditor by the senior management for services other than the audit.

The remuneration to the auditor will be approved by the ordinary general meeting. The board of directors will report to the general meeting details of fees for audit work and any fees for other specific assignments.

Non-conformance with the recommendation: None



The power  
to transform

Statement of Comprehensive Income

| PARENT   |          | AMOUNTS IN NOK 1,000                                                             |       | GROUP    |          |
|----------|----------|----------------------------------------------------------------------------------|-------|----------|----------|
| 2017     | 2016     |                                                                                  | Notes | 2017     | 2016     |
| 109,277  | 107,861  | Sales revenues                                                                   | 12,3  | 149,181  | 136,186  |
| 1,730    | 7,441    | Signing fees and milestone revenues                                              | 12,3  | 1,730    | 7,441    |
| 111,007  | 115,302  | Total revenues                                                                   |       | 150,911  | 143,627  |
| -11,677  | -9,163   | Cost of goods sold                                                               | 4     | -12,011  | -9,337   |
| 99,330   | 106,139  | Gross profit                                                                     |       | 138,900  | 134,290  |
| 668      | 209      | Other income                                                                     |       | 0        | 0        |
| -11,293  | -10,386  | Indirect manufacturing expenses                                                  | 5     | -11,293  | -10,386  |
| -32,591  | -22,962  | Research and development expenses                                                | 5     | -32,591  | -22,962  |
| -37,803  | -35,199  | Marketing and sales expenses                                                     | 5     | -96,430  | -79,930  |
| -45,957  | -44,225  | Other operating expenses                                                         | 5     | -43,789  | -36,873  |
| -126,976 | -112,563 | Total other income and expenses                                                  |       | -184,103 | -150,151 |
| -27,646  | -6,423   | Operating profit/loss(-)                                                         |       | -45,203  | -15,861  |
| 5,949    | 32,426   | Financial income                                                                 | 9     | 5,949    | 32,427   |
| -12,848  | -7,318   | Financial expenses                                                               | 9     | -2,326   | -3,787   |
| -6,899   | 25,108   | Net financial profit/loss(-) including PCI shares                                |       | 3,622    | 28,640   |
| -34,546  | 18,685   | Profit/loss(-) before tax                                                        |       | -41,580  | 12,779   |
| 6,883    | 22,530   | Tax expense                                                                      | 10    | 6,883    | 22,530   |
| -27,663  | 41,215   | Net profit/loss(-)                                                               |       | -34,697  | 35,309   |
| 0        | 0        | Currency translation                                                             |       | -507     | -366     |
| 0        | 0        | Total other comprehensive income items that may be reclassified to profit & loss |       | -507     | -366     |
| -27,663  | 41,215   | Comprehensive income                                                             |       | -35,204  | 34,943   |
|          |          | Earnings per share (Amounts in NOK):                                             | 11    |          |          |
|          |          | Basic                                                                            |       | -1.61    | 1.64     |
|          |          | Diluted                                                                          |       | -1.61    | 1.64     |

Statement of Financial Position

| PARENT  |         | AMOUNTS IN NOK 1,000                               |        | GROUP   |         |
|---------|---------|----------------------------------------------------|--------|---------|---------|
| 2017    | 2016    |                                                    | Notes  | 2017    | 2016    |
|         |         | ASSETS                                             |        |         |         |
| 998     | 1,498   | Machinery and equipment                            | 12     | 1,268   | 1,660   |
| 33,315  | 26,390  | Intangible assets                                  | 12     | 33,315  | 26,390  |
| 227,467 | 221,545 | Loan to group company                              | 23     | -       | -       |
| 5,528   | 3,675   | Other investments                                  | 13     | -       | -       |
| 52,903  | 46,020  | Deferred tax asset                                 | 10     | 52,903  | 46,020  |
| 320,211 | 299,128 | Total non-current assets                           |        | 87,486  | 74,070  |
| 18,996  | 16,969  | Inventories                                        | 14     | 19,552  | 17,468  |
| 8,427   | 7,889   | Accounts receivable                                | 15, 17 | 14,573  | 12,323  |
| 11,030  | 11,553  | Other receivables                                  | 15, 17 | 12,119  | 12,750  |
| 128,991 | 167,223 | Cash and short term deposits                       | 15, 18 | 129,368 | 169,239 |
| 167,444 | 203,634 | Total current assets                               |        | 175,613 | 211,781 |
| 487,655 | 502,761 | Total assets                                       |        | 263,099 | 285,851 |
|         |         | EQUITY AND LIABILITIES                             |        |         |         |
| 10,779  | 10,779  | Share capital                                      | 19     | 10,779  | 10,779  |
| 57,740  | 54,773  | Other paid-in capital                              |        | 57,740  | 54,773  |
| 378,576 | 406,240 | Retained earnings                                  |        | 149,561 | 186,391 |
| 447,095 | 471,792 | Total equity                                       |        | 218,080 | 251,943 |
| 4,279   | 3,629   | Pension liabilities                                | 7      | 4,752   | 3,758   |
| 4,279   | 3,629   | Total non-current liabilities                      |        | 4,752   | 3,758   |
| 14,338  | 9,782   | Accounts payable                                   | 21     | 15,081  | 9,909   |
| 3,694   | 2,926   | Employee withholding taxes and social security tax |        | 3,694   | 2,926   |
| 18,250  | 14,632  | Other current liabilities                          | 21     | 21,492  | 17,314  |
| 36,281  | 27,341  | Total current liabilities                          |        | 40,267  | 30,150  |
| 40,560  | 30,969  | Total liabilities                                  |        | 45,019  | 33,908  |
| 487,655 | 502,761 | Total equity and liabilities                       |        | 263,099 | 285,851 |

Oslo, 16 April 2018  
The Board of Directors of Photocure ASA

Jan H. Egberts  
Chairperson

Johanna Holldack  
Director

Gwen Melincoff  
Director

Tom Pike  
Director

Synne H. Røine  
Director

Grannum R. Sant  
Director

Xavier Yon  
Director

Kjetil Hestdal  
President and CEO

## Statement of Changes in Equity

| PARENT<br>(Amounts in NOK 1,000)                           | Issued capital | Treasury shares | Other paid-in equity | Translation reserve | Retained earnings | Total equity |
|------------------------------------------------------------|----------------|-----------------|----------------------|---------------------|-------------------|--------------|
| Equity as of 31 December 2015                              | 10,738         | -6,051          | 49,124               | 0                   | 370,061           | 423,872      |
| Comprehensive income:                                      |                |                 |                      |                     |                   |              |
| Net profit for the year                                    |                |                 |                      |                     | 41,215            | 41,215       |
| Other comprehensive income that may be reclassified to p&l |                |                 | -                    |                     | -                 | 0            |
| Total comprehensive income                                 | 0              | 0               | 0                    | 0                   | 41,215            | 41,215       |
| Transaction with owners:                                   |                |                 |                      |                     |                   |              |
| Capital increase                                           | 41             |                 | 2,374                |                     |                   | 2,415        |
| Sale own shares                                            |                | 984             |                      |                     |                   | 984          |
| Adjustment own shares*                                     |                | 5,036           |                      |                     | -5,036            | 0            |
| Employees' options                                         |                |                 | 3,306                |                     |                   | 3,306        |
| Total transaction with owners                              | 41             | 6,020           | 5,680                | 0                   | -5,036            | 6,705        |
| Equity as of 31 December 2016                              | 10,779         | -31             | 54,804               | 0                   | 406,240           | 471,792      |
| Comprehensive income:                                      |                |                 |                      |                     |                   |              |
| Net profit for the year                                    |                |                 |                      |                     | -27,663           | -27,663      |
| Other comprehensive income that may be reclassified to p&l |                |                 | -                    |                     | -                 | 0            |
| Total comprehensive income                                 | 0              | 0               | 0                    | 0                   | -27,663           | -27,663      |
| Transaction with owners:                                   |                |                 |                      |                     |                   |              |
| Capital increase                                           |                |                 |                      |                     |                   | 0            |
| Sale own shares                                            |                |                 |                      |                     |                   | 0            |
| Employees' options                                         |                |                 | 2,967                |                     |                   | 2,967        |
| Total transaction with owners                              | 0              | 0               | 2,967                | 0                   | 0                 | 2,967        |
| Equity as of 31 December 2017                              | 10,779         | -31             | 57,771               | 0                   | 378,578           | 447,095      |

| GROUP<br>(Amounts in NOK 1,000)                            | Issued capital | Treasury shares | Other paid-in equity | Translation reserve | Retained earnings | Total equity |
|------------------------------------------------------------|----------------|-----------------|----------------------|---------------------|-------------------|--------------|
| Equity as of 31 December 2015                              | 10,738         | -6,051          | 49,130               | 1,045               | 155,198           | 210,060      |
| Comprehensive income:                                      |                |                 |                      |                     |                   |              |
| Net profit for the year                                    |                |                 |                      |                     | 35,309            | 35,309       |
| Other comprehensive income that may be reclassified to p&l |                |                 | -                    | -366                | -                 | -366         |
| Total comprehensive income                                 | 0              | 0               | 0                    | -366                | 35,309            | 34,943       |
| Transaction with owners:                                   |                |                 |                      |                     |                   |              |
| Capital increase                                           | 41             |                 | 2,374                |                     |                   | 2,415        |
| Sale own shares                                            |                | 984             |                      |                     |                   | 984          |
| Adjustment own shares*                                     |                | 5,036           |                      | 241                 | -5,036            | 241          |
| Employees' options                                         |                |                 | 3,300                |                     |                   | 3,300        |
| Total transaction with owners                              | 41             | 6,020           | 5,674                | 241                 | -5,036            | 6,940        |
| Equity as of 31 December 2016                              | 10,779         | -31             | 54,804               | 920                 | 185,471           | 251,943      |
| Comprehensive income:                                      |                |                 |                      |                     |                   |              |
| Net profit for the year                                    |                |                 |                      |                     | -34,697           | -34,697      |
| Other comprehensive income that may be reclassified to p&l |                |                 | -                    | -507                | -                 | -507         |
| Total comprehensive income                                 | 0              | 0               | 0                    | -507                | -34,697           | -35,204      |
| Transaction with owners:                                   |                |                 |                      |                     |                   |              |
| Capital increase                                           |                |                 |                      |                     |                   | 0            |
| Sale own shares                                            |                |                 |                      |                     |                   | 0            |
| Employees' options                                         |                |                 | 2,967                |                     | -1,626            | 1,341        |
| Total transaction with owners                              | 0              | 0               | 2,967                | 0                   | -1,626            | 1,341        |
| Equity as of 31 December 2017                              | 10,779         | -31             | 57,771               | 413                 | 149,148           | 218,080      |

\*) Correction of previous years surplus of sales of own shares

## Statement of Cash Flows

| PARENT  |         | AMOUNTS IN NOK 1,000                                |       | GROUP   |         |
|---------|---------|-----------------------------------------------------|-------|---------|---------|
| 2017    | 2016    |                                                     | Notes | 2017    | 2016    |
| -34,546 | 18,685  | Profit/loss(-) before tax                           |       | -41,580 | 12,779  |
| 12,000  | 7,710   | Ordinary depreciation & amortisation                | 12    | 12,108  | 7,853   |
| -       | -43     | (Gain)/Loss on sale of non-current equipment        |       | -       | -43     |
| -       | -27,280 | (Gain)/Loss on sale of non-current financial assets | 9     | -       | -27,280 |
| -       | -5,130  | Deferred income sale of Metvix & Aktelite           |       | -       | -5,130  |
| 1,114   | 2,855   | Share-based payments expense                        | 6     | 1,341   | 3,541   |
| 650     | 938     | Pension costs                                       | 7     | 891     | 1,068   |
| -2,310  | -2,394  | Interest income                                     | 9     | -2,310  | -2,394  |
| 10,522  | 3,531   | Unrealized currency (gain)/loss loan subsidiary     | 9     |         |         |
| -51     | 107     | Unrealized currency (gain)/loss other               |       | -51     | 107     |
| -       | 635     | Other items                                         |       | -388    | 285     |
| -       | 37,193  | Received payment Galderma                           | 2     | -       | 37,193  |
| -1,540  | -3,990  | Changes in                                          |       |         |         |
| -16     | -842    | - inventories                                       |       | -1,598  | -4,155  |
| 4,556   | 1,610   | - trade and other receivables                       |       | -1,619  | -1,230  |
| 3,897   | -3,642  | - trade and other payables                          |       | 5,172   | 711     |
| -       | -       | - provisions and other accruals                     |       | 4,441   | -4,113  |
| -       | -       | Taxes paid                                          | 10    | -       | -       |
| -5,724  | 29,944  | Net cash flow from operating activities             |       | -23,593 | 19,193  |
| 2,310   | 2,394   | Interest received                                   |       | 2,310   | 2,394   |
| -16,393 | -9,756  | Loan to subsidiary                                  | 23    | -       | -       |
| -888    | -3,388  | Investments in machinery and equipment              | 12    | -1,050  | -3,535  |
| -       | 387     | Sale of fixed assets (sales price)                  |       | -       | 387     |
| -       | 30,674  | Sale of shares                                      | 13    | -       | 30,674  |
| -       | 2,539   | Sale of subscription rights                         | 9     | -       | 2,539   |
| -17,538 | -18,567 | Development expenditures                            | 12    | -17,538 | -18,567 |
| -32,509 | 4,283   | Net cash flow from investing activities             |       | -16,278 | 13,892  |
| -       | -1,270  | Payment of non-current liability                    |       | -       | -1,270  |
| -       | 2,414   | Proceeds from exercise of share options             |       | -       | 2,414   |
| -       | 984     | Sale own shares                                     |       | -       | 984     |
| 0       | 2,128   | Net cash flow from financing activities             |       | 0       | 2,128   |
| -38,233 | 36,355  | Net change in cash during the year                  |       | -39,871 | 35,213  |
| 167,223 | 130,868 | Cash and cash equivalents as of 01 January          |       | 169,239 | 134,026 |
| 128,991 | 167,223 | Cash and cash equivalents as of 31 December         |       | 129,368 | 169,239 |

I. General information

The annual accounts for 2017 for Photocure ASA (the Parent Company) and its subsidiary Photocure Inc (together the Group or Photocure) were approved for publication by the Board of Directors on 16 April 2018.

Photocure ASA is a public limited company domiciled in Norway. The business of the Group is associated with research, development, production, distribution, marketing and sales of pharmaceutical products. The Company’s shares are listed on the Oslo Stock Exchange. The Parent Company’s registered office is Hoffsvæien 4, NO-0275 Oslo, Norway.

II. Basis for preparation of the annual accounts

The annual accounts for the Group and the Parent Company have been prepared on the basis of historical cost, with the exception of in money market funds that is valued at fair value.

The Group and the Parent Company’s annual accounts are prepared in accordance with International Financial Reporting Standards (IFRS) as specified by the International Accounting Standards Board and implemented by the EU as per 31 December 2017.

Photocure has NOK (Norwegian kroner) as its functional currency and presentation currency. In the absence of any statement

to the contrary, all financial information are reported in whole thousands. As a result of rounding adjustments, the figures in the financial statements may not add up to the totals. Photocure performs the sales and distribution of Hexvix in the Nordic market and in the US through its wholly owned subsidiary Photocure Inc under the trade name Cysview.

III. Disclosures regarding new standards not yet effective

IFRS 15 Revenue from contract with customers establishes a comprehensive framework for determining whether, how much and when revenue is recognized. The standard replaces IAS 18 Revenue and related interpretations. IFRS 15 is effective for annual reporting periods beginning on or after 1 January 2018. The new standard contains a new set of principles on when and how to recognize and measure revenue as well as new requirements related to presentation. The core principle in that framework is that revenue should be recognized dependent on the transfer of promised goods or services to the customer for an amount that reflects the consideration which should be received in exchange for those goods or services. The objective of the standard is to provide a five-step approach to revenue recognition that includes identifying contracts with customers, identifying performance obligations, determining transaction prices, allocating transaction prices to performance obligations, and recognizing revenue when or as performance obligations are satisfied.

|                                                                             | As reported at<br>31 December<br>2017 | Estimated<br>adjustments<br>due to<br>adoption of<br>IFRS 9 | Estimated<br>adjustments<br>due to<br>adoption of<br>IFRS 15.A | Estimated<br>adjustments<br>due to<br>adoption of<br>IFRS 15.B | Estimated<br>adjustments<br>opening<br>balance at 1<br>January 2018 |
|-----------------------------------------------------------------------------|---------------------------------------|-------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------|
| Estimated impact of adaption of IFRS 9 and IRFS 15<br>(Amounts in NOK 1000) |                                       |                                                             |                                                                |                                                                |                                                                     |
| Retained earnings                                                           | 149 561                               | -209                                                        | -6 376                                                         | -4 168                                                         | 138 782                                                             |
| Total                                                                       | 149 561                               | -209                                                        | -6 376                                                         | -4 168                                                         | 138 782                                                             |

Statement of Financial Position

A. The Group has assessed the impact of IFRS 15. The adoption of IFRS 15 will have an impact on Photocure’s timing of recognition of sale of goods. The timing effect of recognition of sales of goods is calculated to be approximately NOK 6.4 million in reduction of equity as of January 1, 2018.

B. Under IFRS 15 up-front fees not related to a separate performance obligation will be recognized over the term of the contract upon the delivery of goods. For current contracts the contract term is estimated to be equal to the expiry date of the patents in the relevant market areas. This will result in revenue being deferred compared to revenue recognition under the current standard. There is currently only one material open contract, entered into in 2011 where patents will expire in 2019. Deferred contract revenue as of January 1, 2018 is calculated to NOK 5.9 million while related contract costs have remaining amortization of NOK 1.7 million giving net adjustment of equity NOK 4.2 million.

IFRS 9

IFRS 9 contains a new classification and measurement approach, impairment and hedge accounting rules for financial assets and liabilities. IFRS 9 is effective for annual periods beginning on or after 1 January 2018. Photocure has analyzed the impact of

implementing IFRS 9 Financial Instruments from 1 January 2018. Based on the contracts, financial assets and liabilities currently held by the Group, the impact on Photocure’s financial statements are evaluated to be insignificant. The impact of changing from the incurred loss model under IAS 39 to the expected loss model under IFRS 9 on trade receivables amounts to NOK 0.2 million.

IFRS 16

IFRS 16 introduces a single, on-balance sheet accounting model for lessees. The standard is effective for annual period beginning on or after 1 January 2019. The adoption of IFRS 16 is not expected to have a significant impact on Photocure’s statement of financial position as future lease payments under existing lease contracts are limited, ref. note 12.

There are no other IFRSs or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Group. The new and amended standards and interpretations from IFRS that were adopted by the EU with effect from 2017 did not have any significant impact on the reporting in 2017.



IV. Use of judgements and estimates.

In preparation of these consolidated financial statements, management has made judgments, estimates and assumptions that affect the application of the Group’s accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. Information about judgements made in applying accounting policies that have the most significant effects on the amounts recognized, and information about assumptions and estimation uncertainties that have significant risk of resulting in a material adjustment in the financial statements as of 31 December 2017, are included in the following notes:

- Note 2 Signing fee and milestone payments: whether the Group should recognize these payments received as income.
- Note 6 Fair value of employee share options: uncertainty regarding the use of estimates and discretionary judgment.
- Note 10 Recognition of deferred tax asset: available future taxable profit against which tax losses carried forward can be used.
- Note 12 Development expenditures: key assumptions underlying the capitalized development costs
- Note 23 Long term loan subsidiary: impairment and key assumptions underlying the balance sheet value in parent company

V. Summary of important guidelines for accounting for the Group

A. CLASSIFICATION

Assets/liabilities are classified as current assets/current liabilities when they meet one of the following criteria:

- They are expected to be realized in the Group’s ordinary operating cycle or are kept for sale or consumption;
- They are expected to be realized within 12 months of the balance sheet date; or
- They are in the form of cash or a cash equivalent.
- All other assets/liabilities are classified as fixed assets/long-term liabilities

B. CURRENCY

Monetary items in foreign currencies are converted at closing rate of exchange. In the absence of any statement to the con-

trary, realized and unrealized exchange rate gains and losses are included in financial income or expenses. Transactions in foreign currencies are recorded at the exchange rate on the date of transaction. Assets and liabilities in foreign currencies are translated into NOK at the exchange rate applicable on the balance sheet date.

Income and expenses in foreign subsidiaries are translated into NOK at the average exchange rate for the financial statement period. The assets and liabilities of the foreign subsidiaries are translated to NOK at exchange rates at the reporting date

C. PROPERTY, PLANT AND EQUIPMENT

Tangible fixed assets are recognized at cost less deductions for accumulated depreciation and accumulated impairment losses. Tangible fixed assets are depreciated over the expected useful life of the assets taking any residual value into consideration. Costs incurred for major replacements and upgrades of tangible fixed assets are added to cost if it is probable that the costs will generate future economic benefits for the Group and if the costs can be reliably measured. Ordinary maintenance is expensed as incurred.

Tangible fixed assets are depreciated on a straight-line basis over the estimated useful life of the asset as follows:

|                                  |           |
|----------------------------------|-----------|
| - Production and test equipment  | 5 years   |
| - Furniture and office equipment | 3–5 years |

D. INTANGIBLE ASSETS

Capitalized development expenditures are recognized at cost less accumulated amortization and accumulated impairment losses. The expenditure capitalized includes the costs of services and materials rendered by external suppliers and own pharmaceutical ingredients and devices directly attributable to the development of the product. Internal personal and overhead costs are not capitalized.

Intangible development expenditures are amortized on a straight-line basis in the profit and loss over the remaining patent period for the approved product and indication as follows:

|                       |              |
|-----------------------|--------------|
| - Product development | 4 – 10 years |
|-----------------------|--------------|

E. IMPAIRMENT

Financial assets and tangible & intangible fixed assets that are recognized in the balance sheet, are tested for impairment if there are indications of a permanent loss in value. If the book value of an asset is higher than the recoverable value of the asset,

the loss in value is recognized in profit and loss. The recoverable value is the highest of net sales value and the value in use of the asset. Tangible fixed assets are grouped and measured at the lowest level for determining loss in value.

Previous impairment losses are reversed to the extent that the assets carrying amount does not exceed the carrying amount that would have been determined, net of depreciation and amortization, if no impairment loss had been recognized or taken place.

F. RESEARCH AND DEVELOPMENT COSTS

Research costs are expensed as incurred. Development costs are recognized in the balance sheet as intangible assets only if there is an identifiable asset that is expected to generate future financial benefits, and when the costs of such an asset can be reliably measured. Development costs are recognized in the balance sheet as intangible assets if all the following criteria are fulfilled:

- It is technically possible to complete the asset so that it can be available for use or for sale;
- The purpose is to complete the asset for use or for sale;
- The Group is able to use or sell the asset;
- The asset will provide future financial benefits, a market exists for the asset or the output of the asset or that the asset is useful if it is to be used internally.
- Sufficient technical, financial or other resources are available to carry out the development and to use or sell it, and
- The opportunity exists to reliably measure costs associated with the intangible asset.

When all the criteria listed above have been met, costs related to development are to be recognized in the balance sheet. Development costs that have been expensed in previous accounting periods cannot be recognized in the balance sheet at a later date. Cost-sharing of research and development expenses with license partners is booked as a reduction in costs. The work of the regulatory function and services provided are related to both market expansion and product development. Photocure classifies for this reason the regulatory function into the following two categories:

- Regulatory work and services related to new products or product development based on new clinical trials up to and including phase 3, are classified as R&D costs
- Regulatory work and services for new markets based on existing clinical data are classified as marketing costs

G. INVESTMENT IN SUBSIDIARY COMPANIES

Shares and investments with the aim of long-term ownership are booked in the balance sheet as long-term investments and

are valued at the lower of cost and fair value. Write-downs for permanent declines in value are made on the basis of individual evaluations. Any realized and unrealized profits/losses and any write-downs related to these investments will be booked in the income statement as financial items.

H. INVENTORIES

Raw materials are valued at the lower of cost and net sales value in accordance with the first-in, first-out principle (FIFO). Semi-finished and finished goods are valued at production cost including a mark-up for their share of the indirect production costs based on the FIFO principle.

I. FINANCIAL ASSETS AND LIABILITIES

Financial assets and liabilities are recognized in the balance sheet when the Group enters into a binding agreement in regard to the item.

1. Trade accounts receivable and other receivables are recorded at nominal value.
2. Cash and cash equivalents include, in addition to bank and cash balances, money market funds with securities that have an average life of three months or less.
3. Investments in other shares and securities valued as financial assets are booked at fair value. According to IAS 39, changes in the value of shares is to be booked directly against equity, but a permanent and significant fall in the value of shares is to be booked against profits. Any subsequent increase in the value of shares is to be booked against equity.
4. Interest-bearing liabilities are recognized at fair value at the time of recognition. In subsequent periods, interest-bearing liabilities are booked at amortized cost according to the effective interest method.
5. Trade accounts payable are booked at nominal value.
6. Financial income consists of interest income on bank balances and money market fund as well as exchange rate gains from currency items. Financial expense consists of interest expense on borrowing and exchange rate losses from currency items.

J. REVENUE RECOGNITION

Revenue is booked when it is probable that resources will generate future economic benefits that will accrue to the Group, and the amount of the revenue can be reliably estimated. Payments for the sale of products are recorded on the date of delivery, that is to say when both control and risk essentially have been transferred to the buyer. The return of goods is booked as a reduction of revenue.

Signing payments received in connection with entering into license agreements are booked as revenue according to the content of the agreement in question. Receipt of payments that are non-refundable and where there are no obligations on Photocure associated with the payments, will be considered to be a sale and booked as revenue immediately. Payments in connection with milestone achievements associated with regulatory approvals, launches etc. are booked as revenue when the milestones are achieved. License agreements that give the right to a guaranteed minimum royalty are booked as revenue at the time the prerequisite is fulfilled. Royalty revenue is booked as Sales revenue in line with the licensee’s sale of licensed products.

K. GOVERNMENT GRANTS

Government grants are booked at the same time as the income that it shall generate or the cost that it shall reduce. Grants received for product development or manufacture are first booked as reduction of costs when the conditions for the grant in question have been met and the applications are granted. Grants received for product development that are capitalized, are reported as reduction of gross expenditures and the net expenditures are regarded as the intangible assets.

L. LICENSE COSTS

The Group has entered into agreements with external parties concerning access to technology in the form of license agreements and agreements that allow the use of patented technology. Royalty-based payments on products are booked as an expense in line with the sale of the licensed products, and booked in the income statement as “Cost of goods sold”. License payments associated with signing fees and milestone payments concerning regulatory approval and product launches are booked as an expense when they occur and are reported as “Other operating expenses” in the income statement.

M. PENSIONS

Photocure ASA has an agreement with a life assurance company concerning contribution-based pensions for Photocure’s employees. The contribution plan has been changed from 1 January 2016 and match the revised national regulations for pension. The new contributions are 6% of the employee’s ordinary salary up to 7.1 times the basic amount (G) of the Norwegian National Insurance scheme, and thereafter 16% up to 12 x G. The national insurance cover pension for salaries to 7.1 G. Pension contributions are paid into the employee’s contribution account with the life assurance company. The Company’s payment of contributions is expensed in the period it is accrued. Any pre-

payments made to the contribution fund are recognized in the balance sheet.

Salary to senior management employees above 12 x G is subject to agreements concerning operational coverage of pensions for salary above this level in the form of contribution-based pensions. The calculated contribution constitutes 16% of the employee’s salary above 12 x G. Senior management employed in Photocure Inc receive 4% contribution of annual salary as deferred compensation. The unfunded annual contribution shall vest after 3 years. The calculated pension obligation pursuant to these schemes are interest-bearing.

Photocure Inc matches its employee’s contribution to the 401(k) plan dollar for dollar up to 4% of salary for the employees that elect to join the plan. There is a salary maximum set by the IRS, which was \$270,000 in 2017.

N. SHARE REMURATION AND OTHER BENEFITS RELATED TO SHARE-BASED REMUNERATION

Employees are offered share options to the Company’s shares as an element of the Group’s employee incentive policy. If the Group has a sufficient amount of own shares, the Group may allot own shares instead of issuing new shares when share options are exercised. All share options granted 2014 and later, are offered at strike prices that reflect the market price +10% of the shares at the time of allotment of the rights.

The fair value is expensed over the share options vesting period and the Company’s equity is increased correspondingly. The fair value of share options is calculated according to the Black-Scholes model. Each program is calculated separately with the actual strike price and duration of the program. The share options cease to be valid immediately on the employee’s resignation from the Company. Employer’s social security contributions on outstanding share options are accrued as personnel costs over the vesting period based on the intrinsic value of the rights.

The fair value of the amount payable to employees in respect of restricted shares, which are settled in cash, is recognized as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at settlement date. Any changes in the liability are recognized in profit or loss.



O. TAX

The tax expense in the income statement includes both the income tax payable for the period and changes in deferred tax. Deferred tax in Norway is calculated at rate of 23% and in the USA at an effective rate of 30% on the basis of the temporary differences that exist between the tax value of the assets and liabilities, and their book value.

Liabilities for deferred tax are included for all temporary differences that increase tax, except when the asset in connection with deferred tax arises as a result of the first-time inclusion of an asset or liability in a transaction that is not in a business combination and affects neither the accounting nor the taxable profit or loss at the time of the transaction.

Assets in connection with deferred tax are included for all tax-reducing temporary differences, carry forward of tax deductions and tax losses in the extent that there is objective proof that there will be sufficient taxable profits against which to offset tax-reducing temporary differences, and carry forward of unused tax deductions and tax losses. In the US the tax years 2017 and prior, businesses were able to

offset current taxable income by claiming net operating losses (NOLs), generally eligible for a two-year carryback and 20-year carryforward. Starting in tax year 2018, NOLs cannot be carried back, but can be indefinitely carried forward. In addition, NOLs for tax years beginning in 2018 will be subject to an 80-percent limitation. The 80 percent limitation on NOL deductions applies to losses generated in tax years beginning after December 31, 2017. NOLs generated in 2017 and earlier would retain their 20-year life and be available to offset 100 percent of taxable income, subject to certain limitations. Companies will have to track their NOLs in different buckets based on date (pre and post December 31, 2017)

The book value of assets in connection with deferred tax is reviewed on every balance sheet date and is reduced to the degree that there is no longer any objective proof that there will be sufficient taxable profits to utilize all or parts of assets in connection with deferred tax. Non-recognized assets in connection with deferred tax are reviewed every balance sheet date and are included to the degree that it is probable that future taxable profits will allow the recovery of assets in connection with deferred tax. Each taxable entity in the Group are treated separately.

P. EARNINGS PER SHARE

Earnings per share is calculated on the basis of the profits for the period after tax but before “Other comprehensive income”, divided by a weighted average number of outstanding shares in the period and adjusted for the treasury shares.

The diluted earnings per share are calculated by adjusting the denominator for amounts outstanding on option programs. Anti-dilution effects are not taken into consideration.

Q. PROVISIONS

Provisions are booked when the Group has a liability associated with an event, when it is probable that the liability will have to be settled and when the liability can be measured or estimated.

When the Group expects that all or parts of the liability can be charged on to another party, this recharge will be recorded as an account receivable if there is virtual certain that the other party will pay. The cost associated with a provision will be recorded net in the income statement after deduction for the recharge.

R. CONTINGENT LIABILITIES AND ASSETS

Contingent liabilities are defined as:

- Possible liabilities as a result of earlier events where their existence depends on future events;
- Liabilities that are not included because it is not probable that they will lead to an outflow of resources from the Group;
- Liabilities that cannot be measured with sufficient reliability.

Contingent liabilities are not included in the annual accounts. Notes on significant contingent liabilities are provided, with the exception of contingent liabilities with little probability of occurring.

Contingent assets are not included in the annual accounts, but are reported in cases in which there is a certain likelihood of their resulting in a benefit to the Group.

S. EVENTS AFTER THE BALANCE SHEET DATE

New information regarding the Group’s financial position on the balance sheet date has been taken into account in the annual accounts. Events after the balance sheet date that do not affect the Group’s financial position on the balance sheet date, but which will affect the Group’s financial position in the future, are reported if they are significant.

T. CASH FLOW STATEMENT

The cash flow statement has been prepared in accordance with the indirect method. Cash and cash equivalents consists of cash, bank deposits and other current investments like money market funds.

U. EQUITY

Amounts that are distributed to or contributed by shareholders are included directly in the equity. The Group’s equity is increased in direct relation to the cost of share-based remuneration for employees.

1. The nominal value of treasury shares is presented in the balance sheet as a negative equity element. The net purchase price is entered as a reduction of other paid-in equity. Profits or losses on transactions in treasury shares are not included in the income statement.

2. Transaction charges in connection with equity transactions are included directly in equity after deduction for tax. Only transaction charges that are directly attributable to the equity transaction are included directly in equity.

V. LEASE AGREEMENTS

The decision as to whether an agreement is, or contains, a lease is based on underlying conditions in the transaction and requires an assessment of whether fulfillment of the agreement is dependent on the use of a specific asset and whether this entails a right to use the asset.

The rental sum in operational lease contracts is charged against income on a straight-line basis over the period of the lease. The lease sum is separated from payment for other elements in the agreement, and the amounts are recorded separately.

W. SEGMENT REPORTING

Segments are reported similarly as the internal reporting to the Group’s senior decision makers. Senior decision makers are defined as the Group’s management group. can be reliably measured. Ordinary maintenance is expensed as incurred.



# Notes to the financial statements for 2017

1

## OWN SALES AND LICENSING OF HEXVIX AND CYSVIEW

In 2011 Photocure entered into an agreement with Ipsen Pharma SAS (Ipsen) for marketing, sales and distribution of Hexvix in most of Europe and rest of the world excluding the US, Nordic region and certain other countries.

In August 2015 Photocure appointed BioSyent Pharma Inc. as our exclusive distributor for the commercialization of Cysview in Canada. BioSyent Pharma will fund all costs related to the launch and commercialization of Cysview, which was approved by Health Canada in January 2015.

In May 2015 Photocure appointed Juno Pharmaceuticals as our exclusive distributor for the registration and commercialization of Hexvix in Australia and New Zealand.

In 2016 Hexvix was approved by Australian health authorities and by New Zealand health authorities in 2017.

2

## SIGNING FEES AND MILESTONE REVENUES

Received, non-refundable up-front payments for licensing and milestone payments for Photocure products from license and distribution partners, have been treated as payments associated with the transfer of rights for the product. Amounts received are not subject to netting, and in the view of the management no conditions or future obligations are associated with these payments. Received payments are therefore recognized as income when the conditions are achieved.

Under the terms of the agreement with Juno Pharmaceuticals, Photocure received in 2016 a milestone of EUR 250,000 for the market approval of Hexvix in Australia.

Under the agreement with Galderma entered in 2009, Photocure received in December 2016 the final payment of the remaining EUR 4 million.

Other revenues include sale of active pharmaceutical ingredients (API) and Signing/ Milestone revenues. 2016 revenues were driven by revenue deferrals as well as milestones that are not repeated in the current year. 2017 revenues relate to Bellus Medical, a privately-owned US based cosmetic dermatology company. In April, Photocure and Bellus Medical signed an asset purchase and licensing agreement for Photocure's cosmetic dermatology product Allumera. Under the terms of this agreement, Photocure received USD 200,000 at signing.

3

## OPERATING SEGMENTS

The operating segments follow the current business model for Photocure which consists of two segments: Commercial Franchise and Development Portfolio. The Commercial segment include the Hexvix/Cysview products and is broken down into own sales and partner sales by market segments and other sales. The Development segment is split by development of commercial products and pipeline products. Sales revenue from own sales in Commercial segment consists of Hexvix sales to pharmaceutical wholesalers in Nordic markets and sales of Cysview to hospitals in the US. Sales through partners comprise sales of Hexvix to Ipsen in Europe outside the Nordic region and royalties from sales by Ipsen to end users. Milestone revenue within partner subsegment include signing payments with Juno for Australia & New Zealand.

Other Sales in the Commercial segment consists of the sale of active substances to partners. Milestone revenue in 2016 is the deferred recognition of Metvix revenue from Galderma.

Operating costs are charged directly to the respective segment involved, or allocated by principles reviewed by corporate management. Government research grants are offset against operating expenses. Corporate management review the profitability of the segments on a regular basis and use this information to analyse and manage resource allocations.

| 1 Jan - 31 December 2017             | Commercial Franchise |                    |                |                 | Development Portfolio |                |                |                 |
|--------------------------------------|----------------------|--------------------|----------------|-----------------|-----------------------|----------------|----------------|-----------------|
| Amounts in NOK 1,000                 | Hex/Cys<br>Own sales | Hex/Cys<br>Partner | Other<br>Sales | Total<br>Sales  | Hex/Cys<br>Develop.   | Pipeline       | Total<br>R&D   | Grand<br>Total  |
| Sales Revenues                       | 85,720               | 63,295             | 166            | 149,181         | -                     | -              | -              | 149,181         |
| Milestone revenues                   | -                    | -                  | 1,730          | 1,730           | -                     | -              | -              | 1,730           |
| Cost of goods sold                   | -3,403               | -8,607             | -              | -12,011         | -                     | -              | -              | -12,011         |
| <b>Gross profit</b>                  | <b>82,316</b>        | <b>54,688</b>      | <b>1,895</b>   | <b>138,900</b>  | <b>-</b>              | <b>-</b>       | <b>-</b>       | <b>138,900</b>  |
| Gross profit of sales %              | 96 %                 | 86 %               | 100 %          | 92 %            |                       |                |                | 92 %            |
| R&D                                  | -                    | -                  | -              | -               | -3,905                | -18,991        | -22,896        | -22,896         |
| Sales & marketing                    | -84,022              | -8,320             | -              | -92,342         | -                     | -4,012         | -4,012         | -96,355         |
| Other & allocations                  | -14,195              | -21,208            | -765           | -36,168         | -4,028                | -12,548        | -16,576        | -52,744         |
| <b>Operating expenses</b>            | <b>-98,218</b>       | <b>-29,527</b>     | <b>-765</b>    | <b>-128,510</b> | <b>-7,933</b>         | <b>-35,551</b> | <b>-43,485</b> | <b>-171,995</b> |
| <b>EBITDA</b>                        | <b>-15,901</b>       | <b>25,160</b>      | <b>1,130</b>   | <b>10,390</b>   | <b>-7,933</b>         | <b>-35,551</b> | <b>-43,485</b> | <b>-33,095</b>  |
| <b>Depreciation and Amortization</b> |                      |                    |                | <b>-1,612</b>   |                       |                | <b>-10,496</b> | <b>12,108</b>   |
| <b>EBIT</b>                          |                      |                    |                | <b>8,778</b>    |                       |                | <b>-53,981</b> | <b>-45,203</b>  |

| 1 Jan - 31 December 2016             | Commercial Franchise |                    |                |                 | Development Portfolio |                |                |                 |
|--------------------------------------|----------------------|--------------------|----------------|-----------------|-----------------------|----------------|----------------|-----------------|
| Amounts in NOK 1,000                 | Hex/Cys<br>Own sales | Hex/Cys<br>Partner | Other<br>Sales | Total<br>Sales  | Hex/Cys<br>Develop.   | Pipeline       | Total<br>R&D   | Grand<br>Total  |
| Sales Revenues                       | 69,504               | 61,460             | 5,222          | 136,186         | -                     | -              | -              | 136,186         |
| Milestone revenues                   | -                    | 2,311              | 5,130          | 7,441           | -                     | -              | -              | 7,441           |
| Cost of goods sold                   | -2,701               | -6,635             | -              | -9,337          | -                     | -              | -              | -9,337          |
| <b>Gross profit</b>                  | <b>66,803</b>        | <b>57,136</b>      | <b>10,352</b>  | <b>134,291</b>  | <b>-</b>              | <b>-</b>       | <b>-</b>       | <b>134,291</b>  |
| Gross profit of sales %              | 96 %                 | 89 %               | 100 %          | 93 %            |                       |                |                | 93 %            |
| R&D                                  | -                    | -                  | -              | -               | -4,215                | -13,437        | -17,652        | -17,652         |
| Sales & marketing                    | -68,230              | -7,541             | -              | -75,771         | -                     | -3,555         | -3,555         | -79,326         |
| Other & allocations                  | -11,037              | -16,802            | -632           | -28,472         | -3,187                | -13,661        | -16,848        | -45,320         |
| <b>Operating expenses</b>            | <b>-79,268</b>       | <b>-24,343</b>     | <b>-632</b>    | <b>-104,243</b> | <b>-7,401</b>         | <b>-30,654</b> | <b>-38,055</b> | <b>-142,298</b> |
| <b>EBITDA</b>                        | <b>-12,465</b>       | <b>32,793</b>      | <b>9,719</b>   | <b>30,047</b>   | <b>-7,401</b>         | <b>-30,654</b> | <b>-38,055</b> | <b>-8,008</b>   |
| <b>Depreciation and Amortization</b> |                      |                    |                | <b>-2,116</b>   |                       |                | <b>-5,737</b>  | <b>-7,853</b>   |
| <b>EBIT</b>                          |                      |                    |                | <b>27,932</b>   |                       |                | <b>-43,792</b> | <b>-15,861</b>  |

The definition of EBITDA is "Earnings Before Interest, Tax, Depreciation and Amortization".

### Geographical information

The geographical revenue information is based on the location of the customers.

The signing fees and milestone revenue information is described in note 2 and not included in the following table.

| Amounts in NOK 1,000            | Sales revenue  |                |
|---------------------------------|----------------|----------------|
|                                 | 2017           | 2016           |
| Nordic countries                | 43,278         | 39,040         |
| United States                   | 42,607         | 30,465         |
| <b>Own sales</b>                | <b>85,885</b>  | <b>69,505</b>  |
| Partner countries Europe        | 63,296         | 64,423         |
| Partner countries rest of world | 0              | 2,258          |
| <b>Group sale revenues</b>      | <b>149,181</b> | <b>136,186</b> |

4

COST OF GOODS SOLD

Total cost of goods sold include direct materials, services provided by contract manufactures and packaging suppliers, products freights and distribution costs.  
In addition are royalties for in licensing of technology and rights from other parties included.

5

INCOME STATEMENT CLASSIFIED BY NATURE

| Amounts in NOK 1,000                                          | Group |          |          | Parent   |          |
|---------------------------------------------------------------|-------|----------|----------|----------|----------|
|                                                               | Note  | 2017     | 2016     | 2017     | 2016     |
| Sales revenues                                                | 2     | 149,181  | 136,186  | 109,277  | 107,861  |
| Signing fees and milestone revenues                           | 2     | 1,730    | 7,441    | 1,730    | 7,441    |
| Cost of goods sold                                            | 4     | -12,011  | -9,337   | -11,677  | -9,163   |
| Gross profit                                                  |       | 138,900  | 134,290  | 99,330   | 106,139  |
| Other income                                                  |       | 0        | 0        | 668      | 209      |
| Payroll expenses                                              | 6     | -96,271  | -82,385  | -53,597  | -52,821  |
| R&D costs excluding payroll expenses/other operating expenses |       | -12,999  | -7,542   | -12,999  | -7,542   |
| Ordinary depreciation and amortisation                        | 12    | -12,108  | -7,853   | -12,000  | -7,710   |
| Other operating expenses                                      |       | -62,725  | -52,372  | -49,048  | -44,699  |
| Total operating expenses                                      |       | -184,103 | -150,151 | -126,976 | -112,562 |
| Operating profit                                              |       | -45,203  | -15,861  | -27,646  | -6,423   |

| Specification of Other operating expenses: | 2017   | 2016   | 2017   | 2016   |
|--------------------------------------------|--------|--------|--------|--------|
| Marketing expenses                         | 10,760 | 8,147  | 5,248  | 4,495  |
| Profit split coverage US                   | -      | -      | 9,942  | 10,774 |
| Travel expenses                            | 13,852 | 11,591 | 4,411  | 3,880  |
| Patent costs, legal and other fees         | 19,957 | 16,723 | 15,066 | 13,302 |
| Other expenses                             | 18,156 | 15,911 | 14,381 | 12,248 |
| Total other operating expenses             | 62,725 | 52,372 | 49,048 | 44,699 |

6

PERSONNEL EXPENSES

| Amounts in NOK 1,000                                       | Group |        |        | Parent |        |
|------------------------------------------------------------|-------|--------|--------|--------|--------|
|                                                            | Note  | 2017   | 2016   | 2017   | 2016   |
| Salaries                                                   |       | 74,790 | 62,229 | 37,425 | 36,995 |
| Employer's social security contributions on salaries, etc. |       | 7,553  | 7,197  | 5,228  | 5,442  |
| Option costs incl employer's social security contributions |       | 716    | 3,400  | 489    | 2,715  |
| Pension costs                                              | 7     | 4,359  | 4,725  | 3,279  | 3,888  |
| Other benefits                                             |       | 8,853  | 4,833  | 7,176  | 3,782  |
| Total payroll expenses                                     |       | 96,271 | 82,385 | 53,597 | 52,821 |
| No. of full-time equivalent positions                      |       | 60     | 50     | 31     | 29     |

Share-based remuneration

As part of the company's incentive policy, employees have been offered share options to the company's shares (the term 'options' is also used). Allocated share options are vested over three years, one third each year. The rights are no longer valid after five years or immediately on resignation of the employee. No share options are allocated to members of the Board of Directors. For 2017, NOK 1.3 million of share-based payments has been expensed, of which NOK 0.2 million applies to Photocure Inc. The corresponding figure for Photocure in 2016 was NOK 3.5 million of which NOK 0.7 million applied to Photocure Inc. No further options have been granted under the stock option incentive plan after the annual general meeting 27 April 2017.

The number of employee share options and average exercise prices for Photocure, and developments during the year:

|                                   | 2017    |                              | 2016      |                              |
|-----------------------------------|---------|------------------------------|-----------|------------------------------|
|                                   | Number  | Average exercise price (NOK) | Number    | Average exercise price (NOK) |
| Outstanding at start of year      | 951,955 | 36.10                        | 1,119,543 | 39.05                        |
| Granted during the year           | 90,100  | 38.06                        | 354,100   | 40.15                        |
| Forfeited during the year         | 94,627  | 37.35                        | 234,987   | 40.75                        |
| Exercised during the year         | 2,667   | 27.39                        | 116,282   | 29.22                        |
| Expired during the year           | 207,092 | 38.5                         | 170,419   | 48.75                        |
| Outstanding at end of year        | 737,669 | 35.53                        | 951,955   | 36.10                        |
| Vested options as per 31 December | 591,389 | 34.56                        | 620,772   | 35.28                        |

The average weighted life of outstanding share options was 2.5 years at 31 December 2017 and 2.8 years at 31 December 2016. The average weighted fair value of options granted in 2017 was NOK 11.13

The exercise prices and the average life of outstanding share options as per 31 December 2017 were as follows:

| Average remaining life | No. of options | Exercise price NOK |
|------------------------|----------------|--------------------|
| 1 year                 | 96,334         | 27.39              |
| 2 year                 | 274,935        | 32.78              |
| 3 year                 | 294,000        | 40.15              |
| 4 year                 | 72,400         | 38.06              |
| Total                  | 737,669        |                    |

Calculation method for market value of employee share options:

The market value of share options is calculated according to the Black-Scholes method. Volatility is calculated on the basis of the development in the historical share price equal to the lifetime of the options. This assumes that historical volatility indicates future volatility, which is not necessarily the case. Strike prices are set as the listed price plus 10% at the time of allocation. Risk-free interest is based on the interest for Norwegian government bonds. Each option programme is calculated separately with the actual exercise price and duration of the programme. The exercise date for the options is calculated on the basis of historical experience in the company and is differentiated between senior management and other employees. The interest advantage is insignificant and has not been included in the accounts. The table below shows the values that have been used in the model.

|                                  | 2017  | 2016  | 2015  | 2014  |
|----------------------------------|-------|-------|-------|-------|
| Dividends (NOK)                  | 0.00  | 0.00  | 0.00  | 0.00  |
| Expected volatility (%)          | 48.33 | 41.22 | 39.99 | 41.10 |
| Historical volatility (%)        | 48.33 | 41.22 | 39.99 | 41.10 |
| Risk-free interest (%)           | 0.87  | 0.48  | 0.95  | 1.79  |
| Expected life of options (years) | 3.50  | 3.50  | 3.50  | 3.71  |

7

## PENSION COSTS

The Parent Company has a contribution-based pension scheme. The contribution plan was changed in 2016 in order to comply with the legal requirements in regard to compulsory occupational pensions in Norway. As of 31 December 2017 and 31 December 2016, the company had immaterial deposits in the premium and the contribution fund. The Company has entered into pension agreements with senior management in the form of contribution-based pensions for salaries exceeding coverage by insurance. This contribution-based pension liability is interest-bearing.

Photocure Inc matches its employee's contribution to the 401(k) plan dollar for dollar. Photocure's contribution is limited to 4% of the salary.

The pension cost for the year is calculated as follows:

| Amounts in NOK 1,000                                       | Group        |              | Parent       |              |
|------------------------------------------------------------|--------------|--------------|--------------|--------------|
|                                                            | 2017         | 2016         | 2017         | 2016         |
| Total pension costs, contribution scheme in life assurance | 3,468        | 3,657        | 2,629        | 2,950        |
| Total pension costs, company contribution scheme           | 891          | 1,068        | 650          | 938          |
| <b>Total</b>                                               | <b>4,359</b> | <b>4,725</b> | <b>3,279</b> | <b>3,888</b> |

8

## AUDITING FEES

| Amounts in NOK 1,000 ex VAT       | Group and parent |            |
|-----------------------------------|------------------|------------|
|                                   | 2017             | 2016       |
| Statutory auditing                | 435              | 300        |
| Other attestation services        | 23               | 55         |
| Other services excluding auditing | -                | -          |
| Tax advice                        | 85               | 390        |
| <b>Total</b>                      | <b>543</b>       | <b>745</b> |

9

## FINANCIAL INCOME AND EXPENSE

| Amounts in NOK 1,000                    | Group        |               | Parent        |               |
|-----------------------------------------|--------------|---------------|---------------|---------------|
|                                         | 2017         | 2016          | 2017          | 2016          |
| Interest income                         | 2,359        | 2,394         | 2,359         | 2,394         |
| Foreign exchange gains                  | 3,590        | 2,753         | 3,590         | 2,753         |
| Gain sale of shares PCI Biotech Holding | -            | 24,741        | -             | 24,741        |
| Gain sale of financial rights           | -            | 2,539         | -             | 2,539         |
| <b>Total financial income</b>           | <b>5,949</b> | <b>32,426</b> | <b>5,949</b>  | <b>32,426</b> |
| Foreign exchange losses                 | 2,107        | 3,701         | 12,629        | 7,233         |
| Other financial expense                 | 219          | 86            | 219           | 86            |
| <b>Total financial expense</b>          | <b>2,326</b> | <b>3,787</b>  | <b>12,848</b> | <b>7,318</b>  |

The foreign exchange loss in the parent company include unrealised exchange loss of the long term loan to the subsidiary that is nominated in USD. The exchange rate NOK/USD decreased to 8.24 as of December 31, 2017 compared to exchange rate of 8.65 at end of previous year. This is resulting in an unrealised loss of NOK 10.5 million in 2017 compared to a loss of NOK 3.5 million in 2016.

In the consolidated accounts the unrealised gain/loss is eliminated against the change in equity as part of other comprehensive income.

A currency forward contract of EUR 3 million that was settled in December 2016 resulted in a currency gain of NOK 1 million.

Photocure has in December 2016 sold all shares in PCI Biotech Holding ASA and realised a gain of NOK 24.7 million. The subscription rights related to the capital increase in PCI Biotech Holding in January 2015 and December 2016 were sold as well.

10

## TAX

| Amounts in NOK 1,000                    | Parent & Group  |                 |
|-----------------------------------------|-----------------|-----------------|
|                                         | 2017            | 2016            |
| <b>Income tax expense</b>               |                 |                 |
| Tax payable                             | -               | -               |
| Changes in deferred tax                 | -6,883          | -22,530         |
| <b>Total income tax expense</b>         | <b>-6,883</b>   | <b>-22,530</b>  |
| <b>Tax base calculation</b>             |                 |                 |
| Profit before income tax                | -34,546         | 18,685          |
| Permanent differences *)                | -3,618          | -27,426         |
| Temporary differences                   | 26,568          | 19,044          |
| Utilisation of tax loss carried forward | -               | -10,303         |
| Increase tax loss carried forward       | 11,596          | -               |
| <b>Tax base</b>                         | <b>-</b>        | <b>-</b>        |
| <b>Temporary differences:</b>           |                 |                 |
| Receivables                             | -               | -               |
| Inventories                             | -2,602          | 1,460           |
| Non current assets                      | -1,411          | -1,349          |
| Long term currency loans                | 59,588          | 69,694          |
| Provisions                              | -               | -625            |
| Pensions                                | -4,207          | -3,534          |
| Gains and loss account                  | 49,160          | 61,450          |
| <b>Total</b>                            | <b>100,528</b>  | <b>127,096</b>  |
| Tax loss carried forward                | -330,542        | -318,841        |
| <b>Net temporary differences</b>        | <b>-230,014</b> | <b>-191,745</b> |
| <b>Deferred tax liability (asset)</b>   | <b>-52,903</b>  | <b>-46,019</b>  |

| Amounts in NOK 1,000                               | Parent & Group |                 |
|----------------------------------------------------|----------------|-----------------|
|                                                    | 2017           | 2016            |
| <b>Reconciliation of effective tax rate:</b>       |                |                 |
| Expected income taxes at statutory tax rate        | -8,291         | 4,671           |
| Permanent differences                              | -868           | -6,857          |
| Effect change permanent differences previous years | -              | 267             |
| Effect change tax rate Norway                      | 2,300          | 1,917           |
| Recognition of previously unrecognized tax losses  | -25            | -22,530         |
| Income tax expense                                 | -6,883         | -22,530         |
| <b>Effective tax rate in % **)</b>                 | <b>19.9 %</b>  | <b>-120.6 %</b> |

Temporary differences are recognized for the parent company only and the note disclosure for the Group is of this reason identic to the disclosure for parent company.

\*) Permanent differences consist of non deductible costs, non taxable income and deduction for development cost through the SkatteFunn concept.

\*\*) Tax expense related to profit before tax.

The parent company has a taxable loss in 2017 of NOK 11.6 million compared to income in 2016 of NOK 10.3 million. Photocure apply a profit/loss split method for the business in US and a transfer of loss carried forward from the subsidiary Photocure Inc in US of NOK 88.6 million was approved by the Norwegian Tax Office in 2016. The basis for recognition of a tax asset in Norway are the predicted future profit according to the business plan for all major markets and that temporary differences for the coming years will be reversed. The deferred tax asset is of this reason increased by NOK 6.9 million as of 31 December 2017 to NOK 52.9 million.

It is Photocure's judgment that the operation in the US will be profitable and this will contribute to the pre-tax result in the parent company through the profit/loss split method. This is based on a cash flow model taking into account a balanced view of the market share for Cysview in the US compared to partner sales of Hexvix in Europe and Photocure's own sales in the Nordic region. The expansion of the US sales and marketing force which commenced in 2017, will continue in 2018 and enable Photocure Inc to cover larger parts of the US market in order to gain further market shares. Furthermore, in 2017 a significant milestone was reached in the US as cystoscopy with Cysview was decided to be reimbursed by the US Health Care at hospital outpatient departments from January 2018. This decision provides strong recognition of the clinical benefits of Cysview/Hexvix and is an important foundation for future growth in the US.

Photocure continues to see growth opportunities in the Nordic and major European countries, not at least in the surveillance market with flexible cystoscopes which is 2-3 times bigger than the rigid cystoscopy market. Several studies have been published highlighting and verifying key clinical benefits including the positive impact of Hexvix/Cysview on reduced disease progression, bladder cancer detection and the safety of repeated use of Hexvix/Cysview.

The basis for the recognition of the tax asset is the assessment that there are convincing evidence that the deferred tax benefit will be utilised.

There is no expiry on losses to be carried forward in Norway while it expires after 20 years in US according to tax legislation valid to end of 2017. The new US tax legislation valid for taxable years from 2018 have no expiry of loss carried forward but a 80% limit in utilization.

Deferred tax assets have not been recognised in respect of the following items in the US subsidiary due to no history of pre-tax profit at this point in time :

| Amounts in NOK 1,000                 | 2017          |               | 2016          |               |
|--------------------------------------|---------------|---------------|---------------|---------------|
|                                      | Amount        | Tax effect    | Amount        | Tax effect    |
| Unrecognised deferred tax assets     |               |               |               |               |
| Net deductible temporary differences | -1,815        | -545          | -1,073        | -429          |
| Tax losses                           | 91,280        | 27,384        | 80,988        | 32,395        |
| <b>Total</b>                         | <b>89,465</b> | <b>26,840</b> | <b>79,915</b> | <b>31,966</b> |

Tax losses for which no deferred tax asset was recognized, expire as follows :

| Amounts in NOK 1,000 | 2017   |             | 2016   |             |
|----------------------|--------|-------------|--------|-------------|
|                      | Amount | Expiry date | Amount | Expiry date |
| Expire               | 91,280 | 2030 - 2037 | 80,988 | 2030 - 2036 |
| Never expire         |        | -           | 105    | -           |

## 11

## EARNINGS PER SHARE

Earnings per share are calculated on the basis of the profit/loss for the year after tax but excluding other comprehensive items. The result is divided by a weighted average number of outstanding shares over the year, reduced by acquisition of treasury shares. The diluted earnings per share is calculated by adjusting the average number of outstanding shares by the number of employee share options that can be exercised. Antidilution effects are not taken into consideration.

|                                                               | 2017              | 2016              |
|---------------------------------------------------------------|-------------------|-------------------|
| <b>Figures indicate the number of shares</b>                  |                   |                   |
| Ordinary shares 1 January                                     | 21,557,910        | 21,476,295        |
| Effect of treasury shares                                     | -809              | -809              |
| Effect of share options exercised                             | -                 | -54,730           |
| Effect of shares issued                                       | -                 | 81,615            |
| <b>Weighted average number of shares, 31 December</b>         | <b>21,557,101</b> | <b>21,502,371</b> |
| Effect of outstanding share options                           | 10,175            | 128,971           |
| <b>Weighted average number of diluted shares, 31 December</b> | <b>21,567,276</b> | <b>21,631,342</b> |

|                                   | 2017  | 2016 |
|-----------------------------------|-------|------|
| Earnings per share                |       |      |
| Earnings per share in NOK basic   | -1.61 | 1.64 |
| Earnings per share in NOK diluted | -1.61 | 1.64 |

## 12

## INTANGIBLE ASSETS, MACHINERY AND EQUIPMENT

| Amounts in NOK 1,000                                |                     |                  |               |                         |              |              |
|-----------------------------------------------------|---------------------|------------------|---------------|-------------------------|--------------|--------------|
| Group                                               | Intangible assets   |                  |               | Machinery and Equipment |              |              |
|                                                     | Product Development | Software Systems | Total         | Production              | Office       | Total        |
| Accumulated cost at 31 December 2015                | 14,405              | 0                | 14,405        | 3,327                   | 5,195        | 8,522        |
| Additions                                           | 18,567              | 2,811            | 21,378        | 0                       | 710          | 710          |
| Disposals and scrapping                             | 0                   | 0                | 0             | -3                      | -760         | -763         |
| Accumulated cost at 31 December 2016                | 32,972              | 2,811            | 35,783        | 3,324                   | 5,145        | 8,469        |
| Additions                                           | 17,538              | 622              | 18,160        | 0                       | 428          | 428          |
| Disposals and scrapping                             | 0                   | 0                | 0             | 0                       | -350         | -350         |
| <b>Accumulated cost at 31 December 2017</b>         | <b>50,510</b>       | <b>3,433</b>     | <b>53,943</b> | <b>3,324</b>            | <b>5,223</b> | <b>8,547</b> |
| Accumulated depreciation at 31 December 2015        | 2,528               | 0                | 2,528         | 2,557                   | 3,676        | 6,233        |
| Amortization and depreciation                       | 6,818               | 47               | 6,865         | 384                     | 603          | 987          |
| Disposals and scrapping                             | 0                   | 0                | 0             | -9                      | -402         | -411         |
| Accumulated depreciation at 31 December 2016        | 9,346               | 47               | 9,393         | 2,932                   | 3,877        | 6,809        |
| Amortization and depreciation                       | 10,673              | 562              | 11,235        | 392                     | 481          | 873          |
| Disposals and scrapping                             | 0                   | 0                | 0             | 0                       | -403         | -403         |
| <b>Accumulated depreciation at 31 December 2017</b> | <b>20,019</b>       | <b>609</b>       | <b>20,628</b> | <b>3,324</b>            | <b>3,955</b> | <b>7,279</b> |
| <b>Book value at 31 December 2017</b>               | <b>30,491</b>       | <b>2,824</b>     | <b>33,315</b> | <b>0</b>                | <b>1,268</b> | <b>1,268</b> |
| <b>Book value at 31 December 2016</b>               | <b>23,626</b>       | <b>2,764</b>     | <b>26,390</b> | <b>392</b>              | <b>1,268</b> | <b>1,660</b> |

The note for parent company has immaterial differences to the group and is not disclosed of this reason.

The Group cannot render probable future earnings large enough to justify recognizing development costs for pharmaceuticals and medical equipment in the balance sheet before marketing approval has been obtained. Own development costs are therefore recognized as an expense until national market approval for the product and indication has been granted. Development expenditures for the product after marketing approval has been obtained and market launch is completed, may be recognized in the balance sheet. The premise of this presentation is based on development that involves significant changes to the product, which is considered likely to generate future financial benefits.

Photocure has from 2015 carried out a clinical study in US for the approved product Cysview in order to file a marketing approval application for repeated use and use in combination with flexible cystoscopies in US. Photocure has in 2017 capitalized NOK 17.5 million in the balance sheet and accumulated NOK 45.8 million as of 31 December 2017 for these development expenditures. The development expenditures are amortized on a straight-line basis in the profit and loss from the start of the expenditure project over the remaining patent period for the approved product and indication. The study addressed safety and efficacy questions regarding repeat use of Cysview and safety and efficacy in the detection of pre-cancerous lesions (CIS).

In addition to fulfill the post marketing commitments in US, the results of the study has been used to expand the indication for use of Cysview. An indication including repeat use, CIS lesions and flexible scope will increase the market potential considerably.

The study was completed in 2017 and included apr 300 patients at 17 sites. The application for the fulfillment of the post marketing committments and expanded indications was filed with FDA in August 2017. Photocure has in February 2018 received an unconditional approval from FDA. The supplier of the flexible scope has also filed and received approval for their flexible scope that in US is required for the use of Cysview.

| Rental costs              | Group |       | Parent |       |
|---------------------------|-------|-------|--------|-------|
|                           | 2017  | 2016  | 2017   | 2016  |
| Rental of office premises | 3,808 | 3,317 | 2,893  | 2,516 |
| Rental of equipment       | 912   | 390   | 861    | 349   |
| Total rental costs        | 4,720 | 3,707 | 3,754  | 2,865 |

The parent company has a rental agreement for premises at Hoffsvæien 4 in Oslo ending August 2021. The agreement include a right to sub rent part of the premises and this right has been utilised in 2017. The net rent amounts to NOK 3.2 million for the period 1 January 2018 through 31 December 2018. The net rent for the remaining period until the expiry of the agreement amounts to NOK 8.8 million. Annual regulation of the rent corresponds to the change in the consumer price index.

Photocure Inc rents office premises at Carnegie Center, Princeton, New Jersey from 1 April 2011 through 10 December 2022. Photocure Inc utilised in 2017 an option to increase the space leased by 551 feet and to extend the agreement until 10 December 2022. The rent commitment for the period 1 January 2018 to 31 December 2018 is NOK 1.1 million while the rent for the remaining period until the expiry of the agreement amounts to NOK 4.5 million.

Rental of equipment comprises medical treatment equipment located at hospitals and office equipment. All rental agreements for equipment are short-term.

13

OTHER INVESTMENTS

In the balance sheet of parent company 100% of shares in the subsidiary Photocure Inc are included with book value NOK 5.5 million as of 31 December 2017 and NOK 3.7 million as of 31 December 2016.

As disclosed in Note 9 above, all of the shares in PCI Biotech Holding were realised in December 2016.

14

INVENTORIES

| Rental costs                     | Group     |           | Parent    |           |
|----------------------------------|-----------|-----------|-----------|-----------|
|                                  | 31-Dec-17 | 31-Dec-16 | 31-Dec-17 | 31-Dec-16 |
| Raw materials                    | 1,526     | 1,798     | 1,526     | 1,798     |
| Components                       | 0         | 3,980     | 0         | 3,980     |
| Semi-finished and finished goods | 18,026    | 11,690    | 17,470    | 11,191    |
| Total inventories                | 19,552    | 17,468    | 18,996    | 16,969    |

The raw materials inventory consists of active substances for the pharmaceutical products. Raw materials are valued at cost. Finished and semi-finished goods are valued at full manufacturing cost. Consumption is carried out in accordance with the FIFO principle. Obsolete goods are written down to fair value. Provisions and write-downs of inventories are included in cost of goods sold in the income statement.

Stocks of components comprises technical medical equipment to be used in clinical trials and products that are to be used in the production of technical medical equipment. In April 2017, the Board of Directors announced that the Company will initiate a broad review of possible strategic alternatives for its non-urology assets, Cevira® and Visonac®, in parallel with ongoing partner search. The impact of this decision was to write down the inventory of components by NOK 4 million. The write-down are included in the R&D expenses for 2017.

15

FINANCIAL RISK

The note describes the company's various financial risks and the management of same. In addition, numerical presentations of risk associated with financial risks are included.

(I) Organisation of financial risk management

Photocure has an international business operation and is exposed to currency risk, interest rate risk, commodity price risk, liquidity risk and credit risk. Responsibility for managing financial risk is placed with the management of the company, including financing, interest rate and currency management as well as risk within the business areas and the risk associated with the company's business processes. Financial risk is also monitored by the Board of Directors.

Centralised risk management

Photocure has a centralised finance department. This department ensures the company's financial freedom to act both long and short term, and to monitor and manage financial risk in collaboration with the individual business units within the company. The finance department maintains communication with the company's bank connections, and carries out hedging transactions regarding interest and currency. Required authorisations for borrowing and entering into derivative agreements are to be granted by the Board of Directors. All transactions involving financial instruments are backed by an underlying commercial hedging requirement.

Commercial operations – production, sales and marketing

Photocure manufactures, markets and sells the company's products through own sales organization in the Nordic region and US and through license partners in other countries. Revenues from license partners consist of three elements: sales of products to license partners, royalties from license partners' sales to end users, and milestone revenues. Photocure manufactures the company's products by renowned contract manufacturers in Italy, Spain, Sweden and Austria. Prices of raw materials are a risk factor. Currency risk is mainly related to milestone revenues, sale to partner and royalties which mainly is nominated in EUR and USD. Also Photocure's commercial operations in the US expose Photocure for currency risk against USD as both revenues and expenses are in USD. Currency risks are partly naturally hedged by purchasing goods and services in EUR and USD.

(II) Classes of financial risk

Interest rate risk

Photocure does not have any interest-bearing debt, and the company's interest rate risk is mainly associated with the company's holdings of cash and cash equivalents. The main strategy is to diversify the risk and invest in money market funds and bond funds with low risk, high liquidity and short duration. More than 90% of the investments are denominated in NOK and are not hedged.

Liquidity risk

A main objective of Photocure's financial policy is to ensure that the company has the financial freedom to act both short and long term to achieve strategic and operational goals. Photocure is to have sufficient funds to cover known capital requirements during the forthcoming 12 months in addition to a strategic reserve. The Company monitors the cash flows on long and short term through planning and reporting. Photocure does not have any loan agreements that involve covenants or other financial requirements.

Photocure uses a multi-currency consolidated accounts system that provides flexibility in relation to drawing on multiple currencies.

The following table presents an overview of the maturity structure of the company's financial obligations, based on non-discounted contractual payments:

|                                       | Remaining period  |            |             |           |        |
|---------------------------------------|-------------------|------------|-------------|-----------|--------|
| Amounts in NOK 1,000                  | Less than 1 month | 1-3 months | 3-12 months | 1-5 years | Total  |
| 31-Dec-17                             |                   |            |             |           |        |
| Accounts payable                      | 14,081            | 1,000      | -           | -         | 15,081 |
| Withholding tax and social securities | 1,640             | 2,054      | -           | -         | 3,694  |
| Other current liabilities             | 3,492             | 7,500      | 9,500       | 1,000     | 21,492 |
| 31-Dec-16                             |                   |            |             |           |        |
| Accounts payable                      | 8,909             | 1,000      | -           | -         | 9,909  |
| Withholding tax and social securities | 1,448             | 1,478      | -           | -         | 2,926  |
| Other current liabilities             | 2,814             | 9,500      | 4,500       | 500       | 17,314 |

#### Credit risk

Management of credit risk associated with accounts receivable and other operational receivables is dealt with as a part of the commercial risk and is followed up continuously as a part of normal operations. Photocure is primarily exposed to credit risk associated with accounts receivable and other short-term receivables. Photocure's sales are made to license partners, pharmaceutical wholesalers in the Nordic region and hospitals in USA. The credit risk is limited as the counterparties are large companies that are not related to each other. Photocure's credit risk is considered moderate and the Company does not use credit insurance.

#### Currency risk

As NOK is the Company's presentation currency, Photocure is exposed to translation risk associated with the company's foreign net exposure. Photocure's revenues and costs are incurred in different currencies, primarily EUR, USD, GBP, SEK and DKK. Photocure is therefore exposed to exchange rate fluctuations. The company regularly monitors the need for hedging of large transactions. Bank accounts in foreign currencies are used actively to reduce exposure to all the main currencies, and currency risk is to some degree naturally hedged in EUR, USD, SEK and DKK by having both revenues and costs in the same currency. However Photocure had a cash surplus in EUR and a cash deficit in USD. During 2016 Photocure entered a currency forward contract of EUR 3 million to secure the deferred EUR 4 million milestone payment from Galderma. The contract was settled in December 2016.

| Amounts in NOK 1,000 | Change in the NOK exchange rate | Effect on operating profit/loss |
|----------------------|---------------------------------|---------------------------------|
| 2017                 | + 10 %                          | -4,600                          |
| 2017                 | - 10 %                          | 4,600                           |
| 2016                 | + 10 %                          | -4,881                          |
| 2016                 | - 10 %                          | 4,881                           |

## 16

### FAIR VALUE

The table below analyses financial assets recognised in the balance sheet at fair value according to the valuation method.

The different levels have been defined as follows:

- Level 1: Noted prices in active markets for corresponding assets or liabilities
- Level 2: Available value measurements other than the noted prices classified as Level 1, either directly observable in the form of agreed prices or indirectly as derived from the price of equivalent.
- Level 3: Value measurements of assets or liabilities that are not based on observed market values

| Amounts in NOK 1,000                 |                |         |         |                |
|--------------------------------------|----------------|---------|---------|----------------|
| Market value hierarchy               | Level 1        | Level 2 | Level 3 | Total          |
| Financial assets available for sale: |                |         |         |                |
| - Money market funds                 | 100,983        |         |         | 100,983        |
| <b>Total</b>                         | <b>100,983</b> | -       | -       | <b>100,983</b> |

## 17

### RECEIVABLES

#### Maximum credit risk

The company's maximum credit risk associated with financial instruments corresponds to gross receivables. In a hypothetical situations, where no receivables are actually paid, this would correspond to:

| Amounts in NOK 1,000             | Group         |               | Parent        |               |
|----------------------------------|---------------|---------------|---------------|---------------|
|                                  | 31-Dec-17     | 31-Dec-16     | 31-Dec-17     | 31-Dec-16     |
| Accounts receivable              | 14,573        | 12,323        | 8,203         | 7,812         |
| Accounts receivable intercompany |               |               | 224           | 77            |
| <b>Total</b>                     | <b>14,573</b> | <b>12,323</b> | <b>8,427</b>  | <b>7,889</b>  |
| Royalty                          | 4,548         | 4,803         | 4,548         | 4,803         |
| Other receivables                | 7,572         | 7,947         | 6,482         | 6,750         |
| <b>Total other receivables</b>   | <b>12,119</b> | <b>12,750</b> | <b>11,030</b> | <b>11,553</b> |

Loan to the subsidiary is disclosed in note 23.

| Age breakdown of group accounts receivable | Not yet due | 0-30 days | 30-60 days | 60-90 days | Over 90 days | Total  |
|--------------------------------------------|-------------|-----------|------------|------------|--------------|--------|
| 31 December 2017                           | 10,617      | 2,918     | 364        | 89         | 585          | 14,573 |
| 31 December 2016                           | 10,343      | 1,928     | 52         | -          | -            | 12,323 |

Bad debt loss in 2017 and 2016 has been immaterial. Credit risk and foreign exchange risk in regard to trade accounts receivable are dealt with in more detail in Note 15.

## 18

### CASH AND SHORT TERM DEPOSITS

| Amounts in NOK 1,000                      | Group          |                | Parent         |                |
|-------------------------------------------|----------------|----------------|----------------|----------------|
|                                           | 31-Dec-17      | 31-Dec-16      | 31-Dec-17      | 31-Dec-16      |
| Cash and cash equivalents, restricted (1) | 4,073          | 3,908          | 4,073          | 3,908          |
| Cash and cash equivalents, non-restricted | 24,312         | 23,668         | 23,935         | 21,652         |
| Money market funds, non-restricted        | 100,983        | 141,663        | 100,983        | 141,663        |
| <b>Total</b>                              | <b>129,368</b> | <b>169,239</b> | <b>128,991</b> | <b>167,223</b> |

(1) Restricted cash and cash equivalents at 31 December 2017 include security for employees' withholding tax in of NOK 1.6 million, while the remaining amount refers to deposit for rent of office.

SHARE CAPITAL

Registered share capital in Photocure ASA amounted to:

|                                                 | No. of shares | Nominal value per share NOK | Share capital in NOK |
|-------------------------------------------------|---------------|-----------------------------|----------------------|
| Share capital at 31 December 2016               | 21,557,910    | 0.50                        | 10,778,955           |
| Share capital at 31 December 2017               | 21,557,910    | 0.50                        | 10,778,955           |
| Treasury shares:                                |               |                             |                      |
| Holdings of treasury shares at 31 December 2015 | 35,476        |                             | 17,738               |
| Buy-back of treasury shares                     | 0             | 0.50                        | 0                    |
| Share option exercise                           | -34,667       | 0.50                        | -17,334              |
| Holdings of treasury shares at 31 December 2016 | 809           |                             | 405                  |
| Buy-back of treasury shares                     | 0             | 0.50                        | 0                    |
| Share option exercise                           | 0             | 0.50                        | 0                    |
| Holdings of treasury shares at 31 December 2017 | 809           |                             | 405                  |

All shares have the same voting rights and otherwise the same rights in the Company. Ordinary shares are classified as equity. Expenses that are directly attributable to the issue of ordinary shares are included as a reduction of equity.

At the General Meeting 27 April 2017, the Board of Directors of Photocure ASA was granted authorisation to issue up to 3.2 million shares. Of this authorisation, (a) 2.16 million shares are linked to financing of the Company’s development, while (b) 1.08 million shares are associated with the issue of shares to the Company’s employees. Subscription of shares under the incentive program shall be subscribed at the market price with an addition of 10% at the time of allocation of the employee share options. At the General Meeting the Board of Directors was granted authorisation to purchase treasury shares to a total nominal value of up to 10% of the applicable share capital. The basis for this authorisation to purchase treasury shares is the desire by the Board of Directors to increase the liquidity of the Company’s shares and in connection with the incentive schemes.

All authorisations are valid up until the Ordinary General Meeting in 2018. Previously issued authorisations have expired.

The table below indicates the status of authorisations at 31 December 2017:

| Figures indicate the number of shares                               | Purchase, treasury shares | Ordinary share issue | Employee share issues |
|---------------------------------------------------------------------|---------------------------|----------------------|-----------------------|
| Authorisation issued at the General Meeting on 27 April 2017        | 2,155,791                 | 2,155,791            | 1,077,895             |
| Share issues after the General Meeting on 27 April 2017             | 0                         | 0                    | 0                     |
| Purchase of treasury shares after the General Meeting 27 April 2017 | 0                         | 0                    | 0                     |
| Remaining under authorisations at 31 December 2017                  | 2,155,791                 | 2,155,791            | 1,077,895             |

737 669 share options have been allocated to employees 31 December 2017 (see note 6).

Ownership structure

The major shareholders in Photocure as of 31 December 2017 were:

|                                                   | Shares     | Shareholding |
|---------------------------------------------------|------------|--------------|
| High Seas AS                                      | 2,200,000  | 10.2 %       |
| Fondsfinans Norge                                 | 1,280,000  | 5.9 %        |
| KLP Aksje Norge                                   | 1,202,395  | 5.6 %        |
| Kommunal Landspensjonskasse                       | 948,789    | 4.4 %        |
| MP Pensjon PK                                     | 810,000    | 3.8 %        |
| The Norwegian Radium Hospital Research Foundation | 743,319    | 3.4 %        |
| BNP Paribas Securities                            | 625,264    | 2.9 %        |
| Fondsfinans Global Helse                          | 380,000    | 1.8 %        |
| Eika Norge                                        | 366,009    | 1.7 %        |
| Vicama AS                                         | 329,530    | 1.5 %        |
| Intertrade Shipping AS                            | 300,000    | 1.4 %        |
| Polar Capital Global Healthcare                   | 254,537    | 1.2 %        |
| Netfonds Livsforsikring AS                        | 252,221    | 1.2 %        |
| MYRLID AS                                         | 250,000    | 1.2 %        |
| Rul AS                                            | 244,451    | 1.1 %        |
| Egeland Holding AS                                | 230,000    | 1.1 %        |
| Danske Bank A/S                                   | 220,947    | 1.0 %        |
| Nordnet Livsforsikring AS                         | 210,220    | 1.0 %        |
| Myna AS                                           | 210,000    | 1.0 %        |
| Kjetil Myrliid Aasen                              | 210,000    | 1.0 %        |
| Total of 20 largest shareholders                  | 11,267,682 | 52.3 %       |
| Treasury shares                                   | 809        | 0.0 %        |
| Total other shareholders                          | 10,289,419 | 47.7 %       |
| Total number of shares                            | 21,557,910 | 100.0 %      |

Shares owned, directly or indirectly, by members of the Board of Directors, the President and CEO and senior management and their closely related associates as of 31 December 2017:

| Name                 | Position                                          | No. of shares | No. of share options* |
|----------------------|---------------------------------------------------|---------------|-----------------------|
| Tom Pike             | Director                                          | 3,400         |                       |
| Kjetil Hestdal       | President and CEO                                 | 133,873       | 72,500                |
| Ambaw Bellete        | Head, US Cancer Commercial Operations             | 2,000         | 61,300                |
| Erik Dahl            | Chief Financial Officer                           | 1,000         | 63,500                |
| Inger Ferner Heglund | Vice President Research and Development           | 8,200         | 70,300                |
| Grete Hogstad        | Vice President Strategic Marketing                | 10,500        | 58,000                |
| Espen Njåstein       | Head, Nordic Cancer Commercial Operations         | 5,000         | 64,100                |
| Gry Stensrud         | Vice President Technical Development & Operations | 1,845         | 53,300                |

\* See note 6 for additional information about the share options.

CAPITAL STRUCTURE

The Group is financed by equity and had no interest-bearing debt at 31 December 2017 and 31 December 2016 with exception for the pension liability according to note 7.

ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

| Amounts in NOK 1,000                     | Group     |           | Parent    |           |
|------------------------------------------|-----------|-----------|-----------|-----------|
|                                          | 31-Dec-17 | 31-Dec-16 | 31-Dec-17 | 31-Dec-16 |
| Accounts payable                         | 15,081    | 9,909     | 13,394    | 9,203     |
| Accounts payable, intercompany           |           |           | 943       | 579       |
| Total                                    | 15,081    | 9,909     | 14,338    | 9,782     |
|                                          |           |           |           |           |
| Provision for accrued external R&D costs | 840       | 2,520     | 840       | 2,520     |
| Accrued bonus, holiday pay, salaries     | 15,487    | 10,837    | 12,661    | 8,155     |
| Accrued royalty liability                | 1,153     | 754       | 1,153     | 754       |
| Miscellaneous other accrued costs        | 4,012     | 3,203     | 3,596     | 3,203     |
| Total other current liabilities          | 21,492    | 17,314    | 18,250    | 14,632    |

Accrued royalty liability concerns agreements with external parties for the right to use patented technology. The liability is calculated as royalty on sales of products accrued in the last period and as a share of any signing fees and milestone payments received.  
Accrued bonus, holiday pay, salaries include from 2017 accrual for restricted share allotment in the amount of NOK 4,588 for the Group to be decided by the Board of Directors.

REMUNERATION OF MANAGEMENT AND BOARD OF DIRECTORS

| Amounts in NOK 1,000                      | Directors' fees paid | Salaries paid | Bonuses accrued | Benefits in kind | Pension cost | Total  |
|-------------------------------------------|----------------------|---------------|-----------------|------------------|--------------|--------|
| Senior management 2017                    |                      |               |                 |                  |              |        |
| President and CEO                         |                      | 2,552         | 586             | 88               | 407          | 3,632  |
| Chief Business Officer from May 2017 *)   |                      | 1,848         | 334             | 677              | 120          | 2,978  |
| VP Research and Development               |                      | 1,285         | 147             | 88               | 123          | 1,643  |
| Chief Financial Officer                   |                      | 1,712         | 205             | 18               | 229          | 2,164  |
| VP Strategic Marketing                    |                      | 1,497         | 176             | 93               | 194          | 1,960  |
| VP Technical Development and Operations   |                      | 1,296         | 163             | 18               | 146          | 1,623  |
| Head, US Cancer Commercial Operations *)  |                      | 2,818         | 465             | 217              | 219          | 3,718  |
| Head, Nordic Cancer Commercial Operations |                      | 1,386         | 193             | 20               | 162          | 1,761  |
| Total senior management                   |                      | 14,393        | 2,268           | 1,218            | 1,599        | 19,480 |
| Board of Directors 2017                   |                      |               |                 |                  |              |        |
| Chairperson of the Board                  | 470                  |               |                 |                  |              | 470    |
| Members of the Board                      | 1,080                |               |                 |                  |              | 1,080  |
| Total remuneration                        | 1,550                | 14,393        | 2,268           | 1,218            | 1,599        | 21,030 |
| *) Remunerations paid in USD:             |                      |               |                 |                  |              |        |
| Chief Business Officer                    |                      | 223           | 40              | 82               | 15           | 360    |
| Head, US Cancer Commercial Operations     |                      | 341           | 56              | 26               | 26           | 449    |

Key mangement and Directors transactions

The Group used the professional services of its Chairperson of the Board and one of its Directors in relation to consulting services during 2017. The consulting services relates to work beyond regular board duties. Contracts are based on market rates and conditions for such services. The amount billed by the Director of NOK 183 thousands was paid by Photocure in 2017. The amount due to the Chairperson has not yet been billed but will be maximum NOK 180 thousands.

| Amounts in NOK 1,000                      | Directors' fees paid | Salaries paid | Bonuses accrued | Benefits in kind | Pension cost | Total  |
|-------------------------------------------|----------------------|---------------|-----------------|------------------|--------------|--------|
| Senior management 2016                    |                      |               |                 |                  |              |        |
| President and CEO                         |                      | 2,786         | 475             | 87               | 343          | 3,691  |
| Chief Operating Officer until May 2016 *) |                      | 2,717         |                 | 68               | 175          | 2,960  |
| VP Research and Development               |                      | 1,391         | 136             | 87               | 134          | 1,747  |
| Chief Financial Officer                   |                      | 1,685         | 166             | 17               | 176          | 2,044  |
| VP Strategic Marketing                    |                      | 1,455         | 124             | 91               | 144          | 1,814  |
| VP Technical Development and Operations   |                      | 1,390         | 119             | 17               | 99           | 1,625  |
| Head, US Cancer Commercial Operations *)  |                      | 2,704         | 334             | 207              | 215          | 3,460  |
| Head, Nordic Cancer Commercial Operations |                      | 1,418         | 201             | 18               | 110          | 1,746  |
| Total senior management                   |                      | 15,546        | 1,555           | 590              | 1,396        | 19,087 |
| Board of Directors 2016                   |                      |               |                 |                  |              |        |
| Chairperson of the Board                  | 470                  |               |                 |                  |              | 470    |
| Members of the Board                      | 1,080                |               |                 |                  |              | 1,080  |
| Total remuneration                        | 1,550                | 15,546        | 1,555           | 590              | 1,396        | 20,637 |
| *) Remunerations paid in USD:             |                      |               |                 |                  |              |        |
| Chief Operating Officer                   |                      | 323           | -               | 8                | 21           | 352    |
| Head, US Cancer Commercial Operations     |                      | 322           | 40              | 25               | 26           | 412    |

THE BOARD OF DIRECTORS' DECLARATION ON DETERMINATION OF SALARIES AND OTHER REMUNERATION FOR SENIOR MANAGEMENT 2018

1. General  
This declaration is prepared by the board of directors in Photocure ASA ("Photocure") in accordance with the Norwegian Public Limited Liability Companies Act (the "Companies Act") section 6-16a, for consideration at the annual general meeting on 9 May 2018.

Principles in this declaration regarding allocation of shares, subscription rights, options and any other form of remuneration stemming from shares or the development of the official share price in the company are binding on the board of directors when approved by the general meeting. Such guidelines are described in section 3.2. Other guidelines are precatory for the board of directors. If the board of directors in an agreement deviates from these guidelines, the reasons for this shall be stated in the minutes of the board of directors' meeting.

The principles set out for determination of salaries and other remuneration for the senior management in this declaration shall apply for the financial year 2018 and until new principles are resolved by the general meeting in accordance with the Companies Act. The annual general meeting in 2019 will review how the principles set out in this declaration have been pursued in 2018 and deal with the principles for 2019 in accordance with the Companies Act.

2. Main principles  
Senior management remuneration in Photocure and group companies shall be determined based on the following main principles:

2.1 Remuneration shall be competitive, but not leading  
Senior management remuneration shall, as a general guideline, be suited to attract and retain skilled leaders in order to enhance value creation in the company and contribute to aligned interests between management and the shareholders. Total remuneration should as a general rule be at level with remuneration for senior management in comparable industries, businesses and positions in the country in which the individual manager resides.

2.2 Remuneration shall be motivational  
Senior management remuneration shall be structured to drive motivation and encourage improvements in results and shareholder value. In general, the remuneration consists of five elements: base salary, short term incentives, long term incentives, benefits in kind and pension benefits. The variable remuneration, short term and long term, is linked to value generation for shareholders over time. The variable remuneration is determined both by achievement of individual and Company wide key performance indicators and goals. Instrumental is that the senior manager both individually and as a team can influence achievement of the key performance indicators and goals. The long term incentives are tied to development of the official share price in the Company and in accordance with section 3.2 of this declaration.

2.3 Remuneration shall be comprehensible and acceptable both internally and externally  
The remuneration system shall not be unduly difficult to explain to the general public and should not involve disproportional complexity for the administration.

2.4 Remuneration shall be flexible, allowing adjustments over time

To be able to offer competitive remuneration the Company must have a flexible system that can accommodate changes as Company and mar-  
kets evolve.

3. Principles regarding benefits offered in addition to base salary

The base salary is the main element of the senior manager's remunera-  
tion. Additional and variable remuneration elements are, at time of grant,  
subject to determination of specific maximum amounts depending on  
position.

The following refer to the individual benefits which are granted in addi-  
tion to base salary. Unless specifically mentioned, no special terms, con-  
ditions or allocation criteria apply to the benefits mentioned.

3.1 Additional benefits

3.1.1 Short term incentive / cash bonus scheme

The Company has established a bonus scheme for senior management.  
These schemes are reviewed at least annually. Bonus schemes are tied  
to achievement of operational and financial goals for the Company laid  
down by the board of directors and achievement of personal goals. Per-  
sonal goals for senior management are approved by the board of direc-  
tors at the start of the year.  
The Chief Executive Officer of the Company has a bonus agreement  
of up to 40% of base salary, while other members of the senior man-  
agement team have bonus agreements from 20% to 35% of their base  
salary.

3.1.2 Pension plans and insurance

Senior managers in Norway participate in Photocure ASA's pension  
scheme, which is a contribution scheme that involves payment of  
between 6% and 16% of the employee's base salary up to 12 times the  
basic amount (G) of the Norwegian National Social Security Scheme  
(Folketrygden). Photocure has established pension coverage for senior  
management for salary above 12 G. The scheme is a contribution-based  
operating pension with provisions corresponding to 16% of salary above  
12 G. In the event of resignation, full pension rights are conditional upon  
at least five years' employment, while less than 3-years' employment  
carries no rights. The pension schemes also cover in the event of dis-  
ability.

Senior managers residing in the United States participates in a 401(k),  
a tax-qualified, defined-contribution pension account defined in sub-  
section 401(k) of the Internal Revenue Code. In addition, Photocure Inc.  
has established an additional pension coverage contributing annually an  
amount equal to 4% of salary and earned bonus.  
The Company compensates the senior management for health and life  
insurance plans in line with standard conditions for senior positions, in  
addition to mandatory occupational injury insurance required under Nor-  
wegian law.

3.1.3 Severance schemes

In accordance with detailed regulations, the current Chief Executive Offi-  
cer is entitled to continue to receive his salary for up to 24 months after  
the end of his period of notice. Should the Chief Executive Officer receive  
other income from employment in this period, any such income will be  
offset in full against his continued salary during the last 12 months of the  
period in which he continues to receive salary. Other senior management  
have a period of notice between 3 and 12 months.

3.1.4 Benefits in kind

Senior managers will normally be given the benefits in kind that are com-  
mon market practice, i.e., telephone expenses, a laptop, free broadband  
connection and use, newspapers and car allowance. There are no special  
restrictions on the type of other benefits that can be agreed on.

3.1.5 Loans and guarantees

No loans are granted, nor any security provided for members of the  
senior management team, the board of directors, employees or other  
persons in elected corporate bodies.

3.1.6 Other benefits

It may be used other variable elements in remuneration or awarded other  
special benefits than those mentioned above, provided that this is con-  
sidered expedient for attracting and/or retaining a manager. No special  
limitations have been placed on the type of benefits that can be agreed.

3.2 Binding principles for shares and other types of benefits related to  
shares or share price trends

Senior managers may receive an award up to 30% of annual base salary  
at the time of granting with which the manager is obliged to buy shares  
at fair value in the Company. The award is offered to the senior manag-  
ers according to the Board's discretion.  
The board of directors will take into consideration inter alia the Compa-  
ny's goals and strategies as well as targeted performance for each senior  
manager, when granting the award.

The plan is a performance based remuneration element reflecting the  
underlying long term value creation of the company. The participant  
receiving the grant is required to invest the net amount after tax into  
shares in the Company ("Restricted Stocks"), that will be subject to a  
three years' lock up period. The Company will, on behalf of the partic-  
ipant, seek to facilitate the share purchase with the use of treasury  
shares or share capital increases. The board of directors has decided  
further terms and conditions for the Restricted Stock plan including  
lock-up and termination of employment.

Existing subscription rights issued under the Company's previous stock  
option incentive plan, as resolved by the annual general meeting of the  
Company in 2016 and previous years, will continue in accordance with  
their terms. The board of directors may however, at its discretion, con-  
vert granted stock options to Restricted Stocks based on fair value.

4. Remuneration to senior managers in other Photocure companies

All companies in the Photocure Group are to follow the main principles  
for the determining of senior management salaries and remuneration as  
set out in this declaration. Photocure aims at coordinating management  
remuneration policy and the schemes used for variable benefits through-  
out the group.

5. Statement on executive salary policy and consequences of  
agreements on remuneration in the previous financial year

Remuneration, including pension and insurances, severance schemes,  
benefits in kind and other benefits granted to senior management are  
discussed note 22 to the annual accounts for the financial year 2017.

The annual report and annual accounts for 2017 are available on the  
web site of the Company;  
www.photocure.com.

The agreements entered into with senior management during the finan-  
cial year 2017 are entered into in accordance with the principles for  
determining senior management salaries and remuneration as approved  
by the general meeting in 2017.

The Board believes that the guidelines for share-based remuneration  
promote value creation in the Company and that the impact they have on  
the Company and shareholders is positive.

Senior managers' holdings of shares in Photocure ASA are stated in the note concerning share capital. Allocation and exercise of Share options to  
shares and holdings of Share options for senior managers are presented in the following overview:

|                                           | Share options<br>awarded | Expired share<br>options | Share options<br>exercised | Holding of share<br>options at 31<br>December 2017 | Average<br>exercise price |
|-------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------------------------------|---------------------------|
| Share options for senior management 2017  |                          |                          |                            |                                                    |                           |
| President and CEO                         | -                        | 21,000                   | -                          | 72,500                                             | 36.08                     |
| Chief Financial Officer                   | -                        | 30,000                   | -                          | 63,500                                             | 34.55                     |
| VP Strategic Marketing                    | -                        | 19,800                   | -                          | 58,000                                             | 34.24                     |
| VP Research and Development               | -                        | 20,280                   | -                          | 70,300                                             | 34.39                     |
| VP Technical Development and Operations   | -                        | 20,550                   | -                          | 53,300                                             | 36.42                     |
| Head, US Cancer Commercial Operations     | -                        | 15,300                   | -                          | 61,300                                             | 34.25                     |
| Head, Nordic Cancer Commercial Operations | -                        | 16,350                   | -                          | 64,100                                             | 34.88                     |
| Chief Business Officer                    |                          | -                        | -                          | -                                                  | 0.00                      |
| Total                                     | -                        | 143,280                  | -                          | 443,000                                            |                           |

|                                           | Share options<br>awarded | Expired share<br>options | Share options<br>exercised | Holding of share<br>options at 31<br>December 2017 | Average<br>exercise price |
|-------------------------------------------|--------------------------|--------------------------|----------------------------|----------------------------------------------------|---------------------------|
| Share options for senior management 2016  |                          |                          |                            |                                                    |                           |
| President and CEO                         | 32,500                   | 30,000                   | 25,000                     | 93,500                                             | 36.63                     |
| Chief Financial Officer                   | 25,500                   | -                        | 1,000                      | 93,500                                             | 35.82                     |
| VP Strategic Marketing                    | 21,000                   | 17,250                   | -                          | 77,800                                             | 35.32                     |
| VP Research and Development               | 27,800                   | 19,500                   | -                          | 90,580                                             | 35.31                     |
| VP Technical Development and Operations   | 26,300                   | 22,500                   | 17,000                     | 73,850                                             | 37.00                     |
| Head, US Cancer Commercial Operations     | 22,500                   | -                        | -                          | 76,600                                             | 35.10                     |
| Head, Nordic Cancer Commercial Operations | 27,800                   | -                        | 5,000                      | 80,450                                             | 35.62                     |
| Total                                     | 183,400                  | 89,250                   | 48,000                     | 586,280                                            |                           |

RELATED PARTIES - COMPANIES

**Subsidiary**  
Photocure has established a wholly owned subsidiary in the US, Photocure Inc, in order to carry out the marketing-, selling- and distribution activities for the Cysview product from 2012. Photocure ASA has the ownership to the patent rights and the trade mark and is responsible in the Group for development and manufacturing of the product.

Photocure Inc purchases the completed product from the parent company and distributes in the United States. The transfer price method implemented from 2015 is the profit & loss split method (PSM). The PSM divides the combined profit or loss between the transacting related entities based on what would be anticipated if the entities had been transacting at arm’s length. A contribution analysis for sale of Cysview compares the split of profit or loss between Photocure Inc and Photocure ASA based on the value of the functions performed by each of the related parties, taking account of assets used and the risks assumed by both parties.

Photocure Inc has established its own marketing organization that is partly funded by a loan from its parent company in addition to its own revenues. The transactions between Photocure ASA and Photocure Inc are on terms at arm’s length, except for the loan that is interest free until further notice.

It is Photocure’s judgment that the operation in the US will be profitable. This is based on a cash flow model taking into account a balanced view of the market share for Cysview in the US compared to partner sales of Hexvix in Europe and Photocure’s own sales in the Nordic region. The expansion of the US sales and marketing force which commenced in 2017, will continue in 2018 and enable Photocure Inc to cover larger parts of the US market in order to gain further market shares. Furthermore, in 2017 a significant milestone was reached in the US as cystoscopy with Cysview was decided to be reimbursed by the US Health Care at hospital outpatient departments from January 2018. This decision provides strong recognition of the clinical benefits of Cysview/Hexvix and is an important foundation for future growth in the US.

The application for the fulfillment of the post marketing commitments for US market approval and expanded indications that was filed in 2017, has been approved by FDA in February 2018. The approval expands the indication in the current rigid setting by including the detection of pre-cancerous lesions in bladder cancer patients as well as the repeat use of Cysview.

| Transactions and intercompany balances Photocure Inc: |       |       |
|-------------------------------------------------------|-------|-------|
| Amounts in NOK 1,000                                  |       |       |
|                                                       | 2017  | 2016  |
| Sales of products                                     | 2,539 | 2,139 |
| Sales of services                                     | 668   | 209   |
| Total subsidiary                                      | 3,207 | 2,348 |

|                      | 31-Dec-17 | 31-Dec-16 |
|----------------------|-----------|-----------|
| Accounts receivables | 224       | 77        |
| Long term loan given | 227,467   | 221,545   |
| Accounts payables    | -943      | -579      |
| Total subsidiary     | 226,748   | 221,043   |

|                                                                  |       |       |
|------------------------------------------------------------------|-------|-------|
| Guarantees to bank in favor of subsidiary for requested security | 1,936 | 1,946 |
|------------------------------------------------------------------|-------|-------|

These are for licenses with the States of Maryland, Mississippi and California to sell Cysview and for the office lease deposit

SUBSEQUENT EVENTS

There are no subsequent events after 31 December 2017 that give material impact to the Group financial position as of the balance sheet date.





KPMG AS  
Sarkedalsveien 6  
Postboks 7000 Majorstuen  
0306 Oslo

Telephone +47 04063  
Fax +47 22 60 96 01  
Internet www.kpmg.no  
Enterprise 935 174 627 MVA



To the General Meeting of Photocure ASA

Independent auditor's report

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Photocure ASA. The financial statements comprise:

- The financial statements of the parent company Photocure ASA (the Company), which comprise the Statement of Financial Position as at 31 December 2017, and the Statement of Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flow for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and
- The consolidated financial statements of Photocure ASA and its subsidiaries (the Group), which comprise the Statement of Financial Position as at 31 December 2017 and Statement of Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flow for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion:

- The financial statements are prepared in accordance with the law and regulations.
- The accompanying financial statements give a true and fair view of the financial position of the Company as at 31 December 2017, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the EU.
- The accompanying consolidated financial statements give a true and fair view of the financial position of the Group as at 31 December 2017, and its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the EU.

Basis for Opinion

We conducted our audit in accordance with laws, regulations, and auditing standards and practices generally accepted in Norway, including International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company and the Group as required by laws and regulations, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

1. Deferred tax asset  
Refer to Note 10 Tax in the Company and Group's financial statement

| The Key Audit Matter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | How the matter was addressed in our audit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Photocure has recognized a deferred tax asset of NOK 53 million in the Company and Group's financial statement as of 31 December 2017.</p> <p>The recognized deferred tax asset relates to deductible temporary differences and unused tax losses in the Company in Norway. Management has assessed that there is convincing evidence that taxable profits will be available in the future, against which unused tax losses in Norway can be utilized.</p> <p>We have determined this to be a key audit matter, due to the inherent uncertainty in forecasting the amount of future taxable profits and the reversal of temporary differences.</p> | <p>Our audit procedures included, among others:</p> <ul style="list-style-type: none"><li>• Comparing historical cash flow development in mature markets with expected future cash flows in new markets for Cysview ®</li><li>• Evaluating the appropriateness of key assumptions in the estimated future taxable profit analysis prepared by management, including profit and cash flow growth, the impact of the expiry of patents and the reversal of significant temporary differences</li><li>• Comparing financial performance with the original forecasts, to evaluate the accuracy of management's budgeting process</li><li>• Evaluating management's sensitivity analysis to assess the impact of reasonable changes in key assumptions like future sales in the US for Cysview ®</li><li>• Evaluating the adequacy of the financial statement disclosures in the Company and Group's financial statement.</li></ul> <p>From the evidence obtained, we found management's assessment of the value of the deferred tax assets to be acceptable.</p> |



2. Carrying value of intangible assets

Refer to Note 12 Intangible assets, machinery and equipment in the Company and Group's financial statement

| The Key Audit Matter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | How the matter was addressed in our audit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Photocure has recognized intangible assets of NOK 33 million in Company and Group's financial statement as of 31 December 2017. Photocure has capitalized NOK 17.5 million in the balance sheet during the year ended 31 December 2017 that relates to development costs for the clinical study of Cysview®. Development costs are recognized in the statement of financial position after national marketing approval has been obtained and market launch is completed to the extent this involves significant changes to the product, physical or in the label, which is considered likely to generate future financial benefits.</p> <p>We have determined recognition of the intangible assets to be a key audit matter as there is judgmental elements on whether it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity, and that the cost of the assets can be measured reliably. Further, we have determined intangible assets impairment indicators to be a key audit matter as the existence of such indicators would trigger an impairment test.</p> | <p>Our audit procedures with regards to recognition of intangible assets included, among others:</p> <ul style="list-style-type: none"> <li>Inspecting marketing approvals for Hexvix/Cysview and assessing whether market launch is completed prior to capitalizing expenditures</li> <li>Inspecting material expenditures capitalized in the financial year to assess whether the expenditures relates to the development activity</li> <li>Evaluating the estimated useful economic lives used to determine the annual amortization</li> <li>Evaluating the adequacy of the financial statement disclosures in the Company and Group's financial statement</li> </ul> <p>Our audit procedures with regards to the identification of impairment indicators included, among others:</p> <ul style="list-style-type: none"> <li>Analyzing documentation that the post marketing clinical trial for Cysview® has been finalized in accordance with the project plan and with the expected results Applying our own knowledge of the business and the industry to challenge management in the identification of any indicators of impairments of intangible assets</li> <li>Evaluating the adequacy of the financial statement disclosures in the Company and Group's financial statement</li> </ul> <p>From the evidence obtained, we found management's assessment of recognition of intangible asset as reasonable. Further, we found management's assessment that there are currently no impairment indicators present, acceptable.</p> |



3. Loan to Group company

Refer to Note 23 Related Parties – Companies in the Company and Group's financial statement

| The Key Audit Matter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | How the matter was addressed in our audit                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Photocure ASA has one subsidiary, Photocure Inc, that was established in order to carry out the marketing-, selling- and distribution activities for the Cysview® product in the US. Photocure ASA has a long-term loan to Photocure Inc. that is recognized at NOK 227 million in the Company's financial statement as of 31 December 2017.</p> <p>We have determined impairment of the loan to be a key audit matter, due to the inherent uncertainty in Photocure Inc. and the Group's ability to successfully commercialize the individual product concerned.</p> | <p>Our audit procedures in this area included, among others:</p> <ul style="list-style-type: none"> <li>Challenging management and applying our own knowledge of the business and the industry to identify any indicators of impairment of the loan</li> <li>Assessing the impairment documentation prepared by management</li> <li>Evaluating the appropriateness of key assumptions in the impairment documentation, including profit and cash flow growth, the impact of the expiry of patents, and discount rate and agree these with the relevant key assumptions used in valuation of deferred tax asset.</li> <li>Comparing historical cash flow development in mature markets with expected future cash flows in the US market</li> <li>Evaluating management's sensitivity analysis to assess the impact of reasonable changes in key assumptions like future sales in the US for Cysview®</li> <li>Evaluating the adequacy of the financial statement disclosures in the Company's financial statement.</li> </ul> <p>From the evidence obtained, we found management's assessment of the carrying value of the loan to Photocure Inc. to be acceptable.</p> |

Other information

Management is responsible for the other information. The other information comprises the information in the Annual Report, but does not include the financial statements and our auditor's report.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon with the exception of our report on Other Legal and Regulatory Requirements below.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### Responsibilities of the Board of Directors and the Managing Director for the Financial Statements

The Board of Directors and the Managing Director (Management) are responsible for the preparation in accordance with law and regulations, including fair presentation of the financial statements in accordance with International Financial Reporting Standards as adopted by the EU, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's and the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with laws, regulations, and auditing standards and practices generally accepted in Norway, including ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with laws, regulations, and auditing standards and practices generally accepted in Norway, including ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error. We design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's or the Group's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company and the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company and the Group to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial

statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Board of Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Board of Directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on Other Legal and Regulatory Requirements

##### Opinion on the Board of Directors' report

Based on our audit of the financial statements as described above, it is our opinion that the information presented in the Board of Directors' report and in the statements on Corporate Governance and Corporate Social Responsibility concerning the financial statements, the going concern assumption, and the proposal for the coverage of the loss is consistent with the financial statements and complies with the law and regulations.

##### Opinion on Registration and Documentation

Based on our audit of the financial statements as described above, and control procedures we have considered necessary in accordance with the International Standard on Assurance Engagements (ISAE) 3000, *Assurance Engagements Other than Audits or Reviews of Historical Financial Information*, it is our opinion that management has fulfilled its duty to produce a proper and clearly set out registration and documentation of the Company's accounting information in accordance with the law and bookkeeping standards and practices generally accepted in Norway.

Oslo, 16 April 2018  
KPMG AS

Geir Moen  
State Authorised Public Accountant



# Alternative Performance Measures

(Information provided based on Guidelines on Alternative Performance Measures (APMs) for listed issuers by The European Securities and Markets Authority - ESMA)

Photocure reports certain performance measures that are not defined under IFRS but which represent additional measures used by the Board and management in assessing performance as well as for reporting both internally and to shareholders. Photocure believes that the presentation of these non-IFRS performance measures provides useful information which provides readers with a more meaningful understanding of the underlying financial and operating performance of the Company when viewed in conjunction with our IFRS financial information.

Photocure uses the following alternative performance measures.

### EBITDA & EBIT

We regard EBITDA as the best approximation to pre-tax operating cash flow and reflects cash generation before working capital changes. EBITDA is widely used by investors when evaluating and comparing businesses, and provides an analysis of the operating results excluding depreciation and amortisation. The non-cash elements depreciation and amortization may vary significantly between companies depending on the value and type of assets.

The definition of EBITDA is “Earnings Before Interest, Tax, Depreciation and Amortization”.

The reconciliation to the IFRS accounts is as follows:

| All amounts in NOK 1,000                            | 2017<br>1.1-31.12 | 2016<br>1.1-31.12 |
|-----------------------------------------------------|-------------------|-------------------|
| Gross profit                                        | 138,900           | 134,291           |
| Operating expenses excl amortization & depreciation | -171,995          | -142,298          |
| EBITDA                                              | -33,095           | -8,008            |
|                                                     |                   |                   |
| Amortization & depreciation                         | -12,108           | -7,853            |
| EBIT                                                | -45,203           | -15,861           |

Recurring EBITDA equals EBITDA before one-off items. One-off items are accounting items of a significant and extraordinary nature. In the first quarter Photocure identified the write off of parts and finished goods inventory for Nedax as an one-off item, in total NOK 4.0 million.

### Revenue growth in constant currency

Photocure’s business is conducted internationally and in respective local currency. Less than 90% of the revenue is conducted in Norwegian kroner, our functional currency. Fluctuations in foreign exchange rates may have a significant impact on reported revenue in Norwegian kroner. To eliminate the translational effect of foreign exchange and to better understand the revenue development in the various regions we provide calculated revenue growth information by region and total for the Company.

The average exchange rates used to translate revenues as per the reporting dates were as follows:

|                       | 2017<br>1.1-31.12 | 2016<br>1.1-31.12 |
|-----------------------|-------------------|-------------------|
| USD (NOK per 1 USD)   | 8.27              | 8.40              |
| EUR (NOK per 1 EUR)   | 9.33              | 9.29              |
| DKK (NOK per 100 DKK) | 125.42            | 124.81            |
| SEK (NOK per 100 SEK) | 96.80             | 98.23             |



# Alternative Performance Measures

### Photocure Group – Other Measures

#### In-market sales

A significant share of Photocure’s sales of Hexvix/Cysview, i.e. all sales classified as partner sales and all sales in the Nordic region, goes through partners and distributors. These partners and distributors carry inventory of Hexvix/Cysview. Photocure’s billing and revenue therefore does not necessarily reflect the demand from end users / hospitals at a given point in time as inventory levels may vary over time.

Furthermore, Photocure’s revenue does not reflect the full value of the product in the market, as partners pay a royalty or a purchase price for the product below the price charged the end user.

To capture end user demand the Company’s partners and distributors report their revenue to end users in terms of number of units invoiced and in terms of revenue achieved. Photocure collects this data and consolidate to get the group total in-market sales, in units and in Norwegian kroner.

| All amounts in NOK 1,000 | 2017<br>1.1-31.12 | 2016<br>1.1-31.12 |
|--------------------------|-------------------|-------------------|
| In-market sales          | 256,426           | 241,099           |



## Photocure ASA

| Hoffsvæien 4 | 0275 Oslo, Norway  
| +47 22 06 22 10  
| [info@photocure.no](mailto:info@photocure.no)

## Photocure INC

| 104 Carnegie Center, suite 303  
| Princeton, NJ 08540 USA | +1609 7596500  
| [info@photocure.com](mailto:info@photocure.com)

[www.photocure.com](http://www.photocure.com)